Shahrokh F Shariat

List of Publications by Citations

Source: https://exaly.com/author-pdf/5567447/shahrokh-f-shariat-publications-by-citations.pdf
Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

1,040 papers	42,795 citations	108 h-index	165 g-index
1,114 ext. papers	52,006 ext. citations	4.6 avg, IF	7.29 L-index

#	Paper	IF	Citations
1040	EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. *European Urology*, **2017**, 71, 447-461	10.2	1199
1039	Epidemiology and risk factors of urothelial bladder cancer. *European Urology*, **2013**, 63, 234-41	10.2	1180
1038	EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. *European Urology*, **2013**, 64, 639-53	10.2	906
1037	Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. *Cancer*, **2009**, 115, 1224-33	6.4	739
1036	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. *European Urology*, **2019**, 76, 639-657	10.2	531
1035	Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. *Journal of Urology*, **2006**, 176, 2414-22; discussion 2422	2.5	514
1034	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. *European Urology*, **2018**, 73, 111-122	10.2	507
1033	Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. *JAMA - Journal of the American Medical Association*, **2004**, 291, 1325-32	27.4	503
1032	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. *European Urology*, **2015**, 68, 868-79	10.2	395
1031	European guidelines on upper tract urothelial carcinomas: 2013 update. *European Urology*, **2013**, 63, 1059-71	10.2	360
1030	Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. *Journal of Urology*, **2003**, 170, 1792-7	2.5	293
1029	Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. *European Urology*, **2012**, 61, 679-85	10.2	289
1028	Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. *European Urology*, **2016**, 69, 300-10	10.2	285
1027	Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. *European Urology*, **2012**, 62, 100-14	10.2	276
1026	p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. *Journal of Clinical Oncology*, **2004**, 22, 1014-24	2.2	253
1025	Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. *European Urology*, **2007**, 51, 137-49; discussion 149-51	10.2	248
1024	Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. *Journal of Clinical Oncology*, **2005**, 23, 6533-9	2.2	242

1023	Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. *European Urology*, **2011**, 60, 644-61	10.2	224
1022	Radical versus partial nephrectomy: effect on overall and noncancer mortality. *Cancer*, **2009**, 115, 1465-71	6.4	224
1021	Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. *Journal of Urology*, **2004**, 171, 1844-9; discussion 1849	2.5	221
1020	Urothelial carcinoma of the bladder and the upper tract: disparate twins. *Journal of Urology*, **2013**, 189, 1214-21	2.5	212
1019	Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. *Journal of Clinical Oncology*, **2009**, 27, 612-8	2.2	209
1018	Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. *Urology*, **2001**, 58, 1008-15	1.6	209
1017	Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. *Prostate*, **2014**, 74, 210-6	4.2	208
1016	An updated catalog of prostate cancer predictive tools. *Cancer*, **2008**, 113, 3075-99	6.4	208
1015	Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. *BJU International*, **2014**, 113, 11-23	5.6	198
1014	Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. *Clinical Cancer Research*, **2008**, 14, 4400-7	12.9	197
1013	Stage specific lymph node metastasis mapping in radical cystectomy specimens. *Journal of Urology*, **2004**, 171, 1830-4	2.5	197
1012	The effect of age and gender on bladder cancer: a critical review of the literature. *BJU International* , **2010**, 105, 300-8	5.6	193
1011	Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. *European Urology*, **2014**, 66, 120-37	10.2	190
1010	ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. *European Urology*, **2013**, 63, 4-15	10.2	190
1009	Nomograms provide improved accuracy for predicting survival after radical cystectomy. *Clinical Cancer Research*, **2006**, 12, 6663-76	12.9	188
1008	The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. *Journal of Clinical Oncology*, **2003**, 21, 3573-9	2.2	187
1007	Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. *European Urology*, **2012**, 61, 961-71	10.2	180
1006	Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. *Cancer Epidemiology*, **2013**, 37, 219-25	2.8	178

1005	Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. *European Urology*, **2015**, 67, 241-9	10.2	178
1004	Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. *Journal of Urology*, **2010**, 184, 69-73	2.5	178
1003	Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. *Lancet Oncology, The*, **2007**, 8, 128-36	21.7	176
1002	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. *European Urology*, **2021**, 79, 62-79	10.2	176
1001	Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. *Journal of Urology*, **2009**, 182, 900-6	2.5	172
1000	Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. *Journal of Clinical Oncology*, **2007**, 25, 349-55	2.2	171
999	Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. *European Urology*, **2015**, 68, 238-53	10.2	168
998	Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. *Journal of Urology*, **2006**, 176, 1354-61; discussion 1361-2	2.5	165
997	A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. *Journal of Clinical Oncology*, **2007**, 25, 3576-81	2.2	164
996	Challenges of cancer biomarker profiling. *European Urology*, **2007**, 52, 1601-9	10.2	162
995	Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. *Cancer*, **2008**, 112, 315-25	6.4	160
994	Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. *Journal of Urology*, **2010**, 183, 2165-70	2.5	159
993	Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. *European Urology*, **2013**, 64, 624-38	10.2	156
992	Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. *Journal of Urology*, **2004**, 171, 626-30	2.5	155
991	Impact of gender on bladder cancer incidence, staging, and prognosis. *World Journal of Urology*, **2011**, 29, 457-63	4	154
990	Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. *Journal of Urology*, **2009**, 181, 2482-9	2.5	154
989	Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *European Urology*, **2012**, 61, 818-25	10.2	153
988	Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. *Journal of Urology*, **2010**, 184, 453-8	2.5	151

987	Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. *European Urology*, **2014**, 65, 210-7	10.2	150
986	Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. *European Urology*, **2015**, 67, 74-82	10.2	149
985	Survivin expression is associated with features of biologically aggressive prostate carcinoma. *Cancer*, **2004**, 100, 751-7	6.4	144
984	A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. *European Urology*, **2015**, 67, 1122-1133	10.2	142
983	Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. *European Urology*, **2011**, 60, 484-92	10.2	142
982	Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. *Journal of Urology*, **2005**, 173, 1518-25	2.5	141
981	Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. *European Urology*, **2011**, 60, 205-10	10.2	140
980	Bladder cancer in the elderly. *Urologic Oncology: Seminars and Original Investigations*, **2009**, 27, 653-67	2.8	139
979	Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. *European Urology*, **2012**, 61, 854-5	10.2	138
978	A systematic review of the volume-outcome relationship for radical prostatectomy. *European Urology*, **2013**, 64, 786-98	10.2	136
977	Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. *BJU International*, **2012**, 109, 77-82	5.6	136
976	Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. *BJU International*, **2011**, 107, 898-904	5.6	136
975	A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. *European Urology*, **2011**, 59, 88-95	10.2	136
974	The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. *European Urology*, **2012**, 61, 245-53	10.2	135
973	Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. *Journal of Urology*, **2006**, 175, 2048-53; discussion 2053	2.5	135
972	Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. *Cancer Research*, **2011**, 71, 7376-86	10.1	134
971	Tumor markers in prostate cancer I: blood-based markers. *Acta Oncologica*, **2011**, 50 Suppl 1, 61-75	3.2	133
970	Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. *European Urology*, **2010**, 57, 1072-9	10.2	133

969	Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). *World Journal of Urology*, **2017**, 35, 379-387	4	132
968	Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. *BJU International*, **2009**, 103, 307-11	5.6	131
967	Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. *European Urology*, **2009**, 56, 1-9	10.2	130
966	Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. *European Urology*, **2010**, 57, 1064-71	10.2	129
965	The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. *European Urology*, **2010**, 58, 574-80	10.2	129
964	Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. *BJU International*, **2011**, 108, 701-5	5.6	128
963	Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. *European Urology*, **2014**, 65, 742-54	10.2	127
962	Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. *European Urology*, **2010**, 57, 300-9	10.2	127
961	The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed?. *European Urology*, **2009**, 56, 512-8	10.2	126
960	Critical review of prostate cancer predictive tools. *Future Oncology*, **2009**, 5, 1555-84	3.6	125
959	Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. *European Urology*, **2010**, 57, 575-81	10.2	125
958	Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. *European Urology*, **2007**, 51, 699-706; discussion 706-8	10.2	125
957	Precystectomy nomogram for prediction of advanced bladder cancer stage. *European Urology*, **2006** , 50, 1254-60; discussion 1261-2	10.2	125
956	Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. *European Urology* , **2017**, 72, 804-818	10.2	124
955	Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. *Clinical Cancer Research*, **2006**, 12, 7369-73	12.9	124
954	Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. *BJU International*, **2008**, 101, 1513-8	5.6	122
953	Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. *European Urology*, **2016**, 70, 1052-1068	10.2	122
952	Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. *Journal of Urology*, **2010**, 183, 68-75	2.5	120

951	Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. *Prostate*, **2007**, 67, 614-22	4.2	120
950	Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. *European Urology*, **2012**, 61, 810-7	10.2	119
949	Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. *European Journal of Cancer*, **2013**, 49, 1889-97	7.5	119
948	Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. *Journal of the National Cancer Institute*, **2009**, 101, 114-9	9.7	119
947	A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. *Urology*, **2010**, 75, 118-24	1.6	118
946	Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. *European Urology*, **2010**, 58, 687-700	10.2	118
945	Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. *Journal of Urology*, **2013**, 189, 1662-9	2.5	117
944	Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. *Cancer*, **2007**, 109, 1106-13	6.4	117
943	Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. *Urologia Internationalis*, **2015**, 94, 1-24	1.9	114
942	Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. *European Urology*, **2018**, 73, 925-933	10.2	114
941	Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. *European Urology*, **2014**, 66, 156-63	10.2	114
940	International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. *BJU International*, **2010**, 105, 1402-12	5.6	114
939	Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. *Modern Pathology*, **2007**, 20, 445-59	9.8	112
938	PROSPECTIVE RANDOMIZED COMPARISON OF HIGH ENERGY TRANSURETHRAL MICROWAVE THERMOTHERAPY VERSUS alpha-BLOCKER TREATMENT OF PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. *Journal of Urology*, **1999**, 161, 139-143	2.5	111
937	Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. *European Urology*, **2012**, 62, 696-703	10.2	110
936	Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. *Journal of Urology*, **2007**, 177, 481-7; discussion 487	2.5	110
935	Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. *BJU International*, **2006**, 98, 329-34	5.6	110
934	A population based assessment of perioperative mortality after cystectomy for bladder cancer. *Journal of Urology*, **2009**, 182, 70-7	2.5	109

933	Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. *World Journal of Urology*, **2011**, 29, 481-6	4	108
932	The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. *Clinical Cancer Research*, **2010**, 16, 4461-7	12.9	107
931	Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. *European Journal of Cancer*, **2009**, 45, 3291-7	7.5	107
930	Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. *BJU International*, **2007**, 100, 1254-8	5.6	107
929	Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. *European Urology*, **2011**, 60, 776-83	10.2	106
928	Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. *BJU International*, **2006**, 97, 997-1001	5.6	105
927	Venous thromboembolism after major cancer surgery: temporal trends and patterns of care. *JAMA Surgery*, **2014**, 149, 43-9	5.4	104
926	Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. *Urology*, **2003**, 61, 1140-5	1.6	103
925	Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. *Journal of Clinical Oncology*, **2004**, 22, 1655-63	2.2	102
924	Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. *Journal of Urology*, **2004**, 171, 1122-7	2.5	102
923	Statistical consideration for clinical biomarker research in bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2010**, 28, 389-400	2.8	99
922	Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. *Journal of Urology*, **2004**, 171, 1089-92	2.5	99
921	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. *BJU International*, **2013**, 112, 453-61	5.6	97
920	A non-cancer-related survival benefit is associated with partial nephrectomy. *European Urology*, **2012**, 61, 725-31	10.2	95
919	Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. *European Urology*, **2014**, 66, 361-70	10.2	94
918	Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. *European Urology*, **2014**, 66, 479-86	10.2	94
917	Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. *European Urology*, **2014**, 65, 650-8	10.2	94
916	Predictors of prostate cancer after initial negative systematic 12 core biopsy. *Journal of Urology*, **2004**, 171, 1850-4	2.5	94

915	E-CADHERIN IMMUNOSTAINING OF BLADDER TRANSITIONAL CELL CARCINOMA, CARCINOMA IN SITU AND LYMPH NODE METASTASES WITH LONG-TERM FOLLOWUP. *Journal of Urology*, **2001**, 165, 1473-1479	2.5	91
914	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. *BJU International*, **2011**, 108, 24-30	5.6	90
913	Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database. *Urology*, **2010**, 75, 321-7	1.6	90
912	Characteristics and clinical significance of histological variants of bladder cancer. *Nature Reviews Urology*, **2017**, 14, 651-668	5.5	89
911	Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. *European Urology*, **2013**, 63, 724-32	10.2	87
910	Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. *Journal of Urology*, **2009**, 182, 2177-81	2.5	86
909	Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. *BJU International*, **2010**, 105, 1672-7	5.6	84
908	Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. *Journal of Urology*, **2006**, 176, 919-26; discussion 926	2.5	84
907	Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. *Journal of Urology*, **2013**, 190, 1999-2004	2.5	83
906	Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. *European Urology*, **2010**, 58, 851-64	10.2	83
905	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. *New England Journal of Medicine*, **2021**, 384, 2102-2114	59.2	83
904	Prognostic factors for upper urinary tract urothelial carcinoma. *Nature Reviews Urology*, **2011**, 8, 440-7	5.5	81
903	Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique?. *European Urology*, **2010**, 58, 645-51	10.2	81
902	Survivin: a promising biomarker for detection and prognosis of bladder cancer. *World Journal of Urology*, **2008**, 26, 59-65	4	81
901	Head-to-head comparison of PI-RADS v2 and PI-RADS v1. *European Journal of Radiology*, **2016**, 85, 1125-31	3.17	81
900	Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. *Journal of Urology*, **2009**, 182, 78-84; discussion 84	2.5	80
899	Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2010**, 28, 441-8	2.8	79
898	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. *European Urology*, **2016**, 69, 728-733	10.2	78

897	Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. *Journal of Urology*, **2012**, 188, 398-404	2.5	78
896	Can nomograms be superior to other prediction tools?. *BJU International*, **2009**, 103, 492-5; discussion 495-7	5.6	78
895	Local Therapy Improves Survival in Metastatic Prostate Cancer. *European Urology*, **2017**, 72, 118-124	10.2	77
894	Urine markers for detection and surveillance of bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 222-9	2.8	77
893	Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. *European Urology*, **2014**, 66, 913-9	10.2	77
892	Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. *Journal of Urology*, **2010**, 183, 1744-50	2.5	77
891	Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. *Journal of Urology*, **2003**, 169, 938-42	2.5	77
890	Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. *BJU International*, **2012**, 110, E7-13	5.6	75
889	Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. *European Urology*, **2013**, 64, 456-64	10.2	75
888	Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. *Journal of Urology*, **2010**, 183, 1324-9	2.5	75
887	Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. *Human Pathology*, **2006**, 37, 1568-76	3.7	75
886	E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. *Urology*, **2001**, 57, 60-5	1.6	75
885	Systematic review and meta-analysis of perioperative and oncologic outcomes of laparoscopic cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal tumors. *Journal of Urology*, **2014**, 191, 1209-17	2.5	74
884	Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. *European Urology*, **2012**, 62, 677-84	10.2	74
883	Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. *BJU International*, **2009**, 103, 302-6	5.6	73
882	Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. *Cancer*, **2001**, 92, 2985-92	6.4	73
881	PREOPERATIVE PLASMA LEVELS OF INTERLEUKIN-6 AND ITS SOLUBLE RECEPTOR PREDICT DISEASE RECURRENCE AND SURVIVAL OF PATIENTS WITH BLADDER CANCER. *Journal of Urology*, **2002**, 167, 1475-1481	2.5	73
880	Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016". *European Urology Focus*, **2019**, 5, 457-466	5.1	73

879	The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. *International Journal of Radiation Oncology Biology Physics*, **2010**, 76, 342-8	4	72
878	The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guﬁn. *BJU International*, **2016**, 118, 44-52	5.6	72
877	Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. *Nature Communications*, **2019**, 10, 2977	17.4	71
876	Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. *Journal of Urology*, **2011**, 185, 456-61	2.5	70
875	Nomograms for bladder cancer. *European Urology*, **2008**, 54, 41-53	10.2	70
874	Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. *Journal of Urology*, **2008**, 179, 2164-9	2.5	70
873	Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. *Urology*, **2014**, 83, 863-7	1.6	69
872	Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. *Urology*, **2000**, 56, 735-40	1.6	69
871	Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma?. *Urologic Oncology: Seminars and Original Investigations*, **2011**, 29, 27-32	2.8	68
870	Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. *BJU International*, **2011**, 108, 406-12	5.6	68
869	PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. *Clinical Cancer Research*, **2018**, 24, 6300-6307	12.9	67
868	Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. *Clinical Cancer Research*, **2008**, 14, 3785-91	12.9	67
867	Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. *Journal of Urology*, **2017**, 197, 1419-1426	2.5	66
866	Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. *European Urology*, **2007**, 51, 152-60	10.2	66
865	Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. *European Urology Focus*, **2019**, 5, 205-223	5.1	66
864	The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. *European Urology*, **2018**, 73, 543-557	16.1	66
863	Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. *European Urology*, **2013**, 63, 1082-90	10.2	65
862	Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. *Urologic Oncology: Seminars and Original Investigations*, **2012**, 30, 252-8	2.8	65

861	Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study. *European Urology*, **2010**, 57, 956-62	10.2	65
860	Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. *Human Pathology*, **2007**, 38, 1703-13	3.7	65
859	Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. *World Journal of Urology*, **2011**, 29, 487-94	4	64
858	Highly predictive survival nomogram after upper urinary tract urothelial carcinoma. *Cancer*, **2010**, 116, 3774-84	6.4	64
857	A review of integrated staging systems for renal cell carcinoma. *European Urology*, **2012**, 62, 303-14	10.2	63
856	Response assessment using Ga-PSMA ligand PET in patients undergoing Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 1063-1072	8.8	63
855	A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. *Cancer*, **2011**, 117, 103-9	6.4	62
854	A delay in radical nephroureterectomy can lead to upstaging. *BJU International*, **2010**, 105, 812-7	5.6	62
853	Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. *BJU International*, **2010**, 106, 1216-22	5.6	62
852	Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. *Urology*, **2009**, 73, 142-6	1.6	62
851	Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. *BJU International*, **2013**, 111, 249-55	5.6	61
850	Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). *European Urology*, **2013**, 64, 472-7	10.2	61
849	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. *European Urology*, **2017**, 71, 886-893	10.2	61
848	Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. *BJU International*, **2011**, 108, 1286-91	5.6	61
847	Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. *European Urology*, **2012**, 61, 1069-70	10.2	60
846	Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. *BJU International*, **2013**, 111, E30-6	5.6	60
845	Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 904-8	2.8	60
844	Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist. *Urology*, **2009**, 74, 858-64	1.6	60

843	Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. *Journal of Urology*, **2003**, 170, 985-9	2.5	60
842	Critical evaluation of urinary markers for bladder cancer detection and monitoring. *Reviews in Urology*, **2008**, 10, 120-35	1	60
841	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. *European Urology*, **2020**, 77, 223-250	10.2	60
840	Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. *European Urology*, **2019**, 75, 176-183	10.2	60
839	Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature. *World Journal of Urology*, **2018**, 36, 157-170	4	60
838	Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. *European Urology*, **2013**, 64, 465-71	10.2	59
837	Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. *Journal of Urology*, **2010**, 183, 1757-63	2.5	59
836	Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis. *World Journal of Urology*, **2015**, 33, 563-70	4	58
835	Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. *Urologic Clinics of North America*, **2016**, 43, 47-62	2.9	58
834	BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. *Journal of Urology*, **2014**, 191, 603-10	2.5	58
833	Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. *BJU International*, **2009**, 103, 1359-62	5.6	58
832	Molecular markers in bladder cancer. *World Journal of Urology*, **2019**, 37, 31-40	4	58
831	An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. *World Journal of Urology*, **2019**, 37, 507-514	4	57
830	Smoking and Bladder Cancer: A Systematic Review of Risk and Outcomes. *European Urology Focus*, **2015**, 1, 17-27	5.1	57
829	p53 expression in patients with advanced urothelial cancer of the urinary bladder. *BJU International* , **2010**, 105, 489-95	5.6	57
828	Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. *Clinical Cancer Research*, **2009**, 15, 7012-9	12.9	57
827	The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. *Nature Reviews Urology*, **2016**, 13, 471-9	5.5	57
826	Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma. *World Journal of Urology*, **2015**, 33, 2045-52	4	55

825	Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. *Urology*, **2011**, 77, 660-6	1.6	55
824	Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. *Urology*, **2008**, 71, 302-7	1.6	55
823	Molecular markers in bladder cancer. *Current Opinion in Urology*, **2008**, 18, 1-8	2.8	55
822	Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. *BJU International*, **2017**, 120, 313-319	5.6	54
821	Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. *European Urology*, **2012**, 61, 237-42	10.2	54
820	Conditional survival after radical nephroureterectomy for upper tract carcinoma. *European Urology*, **2015**, 67, 803-12	10.2	54
819	Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. *Urology*, **2003**, 61, 1053-8	1.6	54
818	Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. *BJU International*, **2013**, 112, 1105-12	5.6	53
817	Lymphadenectomy for bladder cancer at the time of radical cystectomy. *European Urology*, **2013**, 64, 266-76	10.2	53
816	An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. *World Journal of Urology*, **2018**, 36, 1981-1995	4	52
815	The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study. *European Urology*, **2014**, 66, 561-8	10.2	52
814	Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series. *European Urology*, **2012**, 61, 715-21	10.2	52
813	Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. *BJU International*, **2012**, 109, 1147-54	5.6	52
812	Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. *Journal of Urology*, **2013**, 190, 480-6	2.5	52
811	Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma--results from a comprehensive multi-centre database (CORONA/SATURN-Project). *BJU International*, **2013**, 112, 909-16	5.6	52
810	Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. *Journal of Urology*, **2010**, 184, 888-94	2.5	52
809	Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. *European Urology*, **2009**, 55, 1124-33	10.2	51
808	Thirty-day mortality after nephrectomy: clinical implications for informed consent. *European Urology*, **2009**, 56, 998-1003	10.2	51

807	European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. *European Urology*, **2021**, 79, 480-488	10.2	51
806	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). *European Urology*, **2021**,	10.2	51
805	Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. *Cancer Research*, **2003**, 63, 4662-70	10.1	51
804	Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. *World Journal of Urology*, **2017**, 35, 337-353	4	50
803	Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?. *Urologic Oncology: Seminars and Original Investigations*, **2011**, 29, 716-23	2.8	50
802	Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. *Journal of Urology*, **2010**, 183, 87-93	2.5	50
801	Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. *BJU International*, **2009**, 103, 1368-74	5.6	50
800	A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. *BJU International*, **2007**, 100, 1015-20	5.6	50
799	Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. *Cancer*, **2001**, 92, 1475-83	6.4	50
798	Gender differences in incidence and outcomes of urothelial and kidney cancer. *Nature Reviews Urology*, **2015**, 12, 585-92	5.5	49
797	The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 68.e1-7	2.8	49
796	Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. *Annals of Surgical Oncology*, **2011**, 18, 2988-96	3.1	49
795	Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective. *Cancer*, **2009**, 115, 5680-7	6.4	49
794	New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. *BJU International*, **2008**, 101, 675-83	5.6	49
793	Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis. *BJU International*, **2014**, 114, 733-40	5.6	48
792	Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. *BJU International*, **2014**, 113, 393-8	5.6	48
791	Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality. *Urology*, **2010**, 75, 376-81	1.6	48
790	Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. *European Urology*, **2009**, 56, 1093-5	10.2	48

789	Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. *Urology*, **2009**, 74, 1070-4	1.6	48
788	Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. *European Urology*, **2007**, 52, 98-105	10.2	48
787	Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer. *Cancer*, **2006**, 106, 1701-7	6.4	48
786	Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. *European Urology*, **2019**, 75, 649-658	10.2	48
785	Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis. *European Urology*, **2013**, 64, 837-45	10.2	47
784	Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. *European Urology*, **2013**, 63, 1049-58	10.2	47
783	Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). *Current Urology Reports*, **2014**, 15, 404	2.9	46
782	Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities. *BJU International*, **2013**, 111, 67-73	5.6	46
781	Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. *International Journal of Urology*, **2012**, 19, 1060-6	2.3	46
780	Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2012**, 30, 666-72	2.8	46
779	Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma. *Journal of Urology*, **2011**, 186, 66-72	2.5	46
778	No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study. *World Journal of Urology*, **2011**, 29, 465-72	4	46
777	Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study. *Journal of Urology*, **2010**, 184, 1895-900	2.5	46
776	Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. *Urology*, **2007**, 70, 482-6	1.6	46
775	Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. *Journal of Clinical Oncology*, **2003**, 21, 1223-31	2.2	46
774	What Is the Significance of Variant Histology in Urothelial Carcinoma?. *European Urology Focus*, **2020**, 6, 653-663	5.1	46
773	Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 335-341	2.8	45
772	Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. *World Journal of Urology*, **2018**, 36, 1703-1709	4	45

771	External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. *Prostate*, **2013**, 73, 211-8	4.2	45
770	In-hospital mortality and failure to rescue after cytoreductive nephrectomy. *European Urology*, **2013**, 63, 1107-14	10.2	45
769	Biomolecular predictors of urothelial cancer behavior and treatment outcomes. *Current Urology Reports*, **2012**, 13, 122-35	2.9	45
768	Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. *International Journal of Urology*, **2012**, 19, 645-51	2.3	45
767	Conditional survival predictions after nephrectomy for renal cell carcinoma. *Journal of Urology*, **2009**, 182, 2607-12	2.5	45
766	Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer. *Clinical Genitourinary Cancer*, **2018**, 16, 445-452	3.3	44
765	Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 389-399	2.8	44
764	Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. *World Journal of Urology*, **2013**, 31, 1029-36	4	44
763	High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 47.e9-14	2.8	44
762	p53 predictive value for pT1-2 N0 disease at radical cystectomy. *Journal of Urology*, **2009**, 182, 907-13	2.5	44
761	Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. *BJU International*, **2013**, 111, 1215-21	5.6	43
760	Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. *Journal of Urology*, **2005**, 174, 2046-50	2.5	43
759	Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. *Journal of Urology*, **2012**, 187, 845-51	2.5	42
758	Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. *Annals of Surgical Oncology*, **2012**, 19, 4337-44	3.1	42
757	Immunohistochemical biomarkers for bladder cancer prognosis. *International Journal of Urology*, **2011**, 18, 616-29	2.3	42
756	Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. *Cancer*, **2011**, 117, 2892-7	6.4	42
755	Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. *International Journal of Cancer*, **2007**, 121, 791-5	7.5	42
754	Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. *BJU International*, **2019**, 123, 959-967	5.6	42

753	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. *BJU International*, **2018**, 121, 252-259	5.6	41
752	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. *Journal of Urology*, **2017**, 198, 1253-1262	2.5	41
751	Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. *World Journal of Urology*, **2011**, 29, 473-80	4	41
750	Transcriptomic heterogeneity in multifocal prostate cancer. *JCI Insight*, **2018**, 3,	9.9	41
749	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. *European Urology*, **2018**, 73, 436-444	10.2	41
748	Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. *European Urology Oncology*, **2018**, 1, 403-410	6.7	41
747	Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 483.e17-483.e24	2.8	40
746	Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. *Journal of Urology*, **2010**, 184, 74-80	2.5	40
745	Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients. *World Journal of Urology*, **2018**, 36, 1019-1029	4	39
744	The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 484.e19-484.e25	2.8	39
743	Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. *Journal of Urology*, **2014**, 191, 316-22	2.5	39
742	Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. *European Urology*, **2013**, 63, 371-8	10.2	39
741	Utility and limitations of 3-Tesla diffusion-weighted magnetic resonance imaging for differentiation of renal tumors. *European Journal of Radiology*, **2014**, 83, 909-913	4.7	39
740	Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. *European Journal of Cancer*, **2012**, 48, 1503-11	7.5	39
739	Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. *European Urology*, **2011**, 59, 1026-31	10.2	39
738	Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. *Journal of Urology*, **2007**, 177, 1163-8	2.5	39
737	Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. *European Urology Focus*, **2020**, 6, 479-489	5.1	39
736	Comparative analysis of oncologic outcomes of partial ureterectomy vs radical nephroureterectomy in upper tract urothelial carcinoma. *Urology*, **2013**, 81, 972-7	1.6	38

735	Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. *Journal of Urology*, **2012**, 187, 457-62	2.5	38
734	Predictive factors of recurrence and survival of upper tract urothelial carcinomas. *World Journal of Urology*, **2011**, 29, 495-501	4	38
733	Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. *European Urology*, **2015**, 68, 949-56	10.2	37
732	Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1-pT3a localized renal cell carcinoma in a comprehensive multicenter study of the CORONA project. Can we improve prognostic discrimination for patients with stage pT3a tumors?. *European Urology*, **2015**, 67, 943-51	10.2	37
731	Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 1078-87	2.8	37
730	The effect of marital status on stage and survival of prostate cancer patients treated with radical prostatectomy: a population-based study. *Cancer Causes and Control*, **2011**, 22, 1085-95	2.8	37
729	Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. *European Urology*, **2010**, 58, 112-7	10.2	37
728	Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. *Clinical Cancer Research*, **2008**, 14, 1418-22	12.9	37
727	Marital status: a gender-independent risk factor for poorer survival after radical cystectomy. *BJU International*, **2012**, 110, 1301-9	5.6	36
726	Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma. *World Journal of Urology*, **2017**, 35, 535-548	4	35
725	Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. *BJU International*, **2013**, 111, 404-11	5.6	35
724	Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. *Journal of Urology*, **2012**, 187, 418-23	2.5	35
723	Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. *Urology*, **2009**, 74, 373-7	1.6	35
722	Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. *Urologic Oncology: Seminars and Original Investigations*, **2007**, 25, 468-75	2.8	35
721	Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. *European Urology*, **2020**, 78, 893-906	10.2	35
720	Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy?. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 21.e1-21.e9	2.8	34
719	Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer. *World Journal of Urology*, **2015**, 33, 105-10	4	34
718	Robotic-assisted radical cystectomy with extracorporeal urinary diversion for urothelial carcinoma of the bladder: analysis of complications and oncologic outcomes in 175 patients with a median follow-up of 3 years. *Urology*, **2013**, 82, 1323-9	1.6	34

717	Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. *Prostate*, **2009**, 69, 886-94	4.2	34
716	Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. *Clinical Cancer Research*, **2008**, 14, 3362-6	12.9	34
715	Metformin association with lower prostate cancer recurrence in type 2 diabetes: a systematic review and meta-analysis. *Asian Pacific Journal of Cancer Prevention*, **2015**, 16, 595-600	1.7	34
714	Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. *European Urology Oncology*, **2018**, 1, 91-100	6.7	34
713	Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification. *European Urology*, **2012**, 62, 224-31	10.2	33
712	Sex disparities in cancer mortality: the risks of being a man in the United States. *Journal of Urology*, **2013**, 189, 1470-4	2.5	33
711	Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. *BJU International*, **2014**, 114, 674-9	5.6	33
710	Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. *BJU International*, **2014**, 113, 70-6	5.6	33
709	Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. *Journal of Urology*, **2012**, 188, 2120-7	2.5	33
708	Annual surgical caseload and open radical prostatectomy outcomes: improving temporal trends. *Journal of Urology*, **2010**, 184, 2285-90	2.5	33
707	Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. *European Urology*, **2004**, 45, 304-13; author reply 313	10.2	33
706	Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. *Urology*, **2000**, 56, 423-9	1.6	33
705	An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer. *Biomolecules*, **2016**, 6,	5.9	33
704	Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. *European Urology Focus*, **2019**, 5, 224-241	5.1	33
703	Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. *Journal of Surgical Oncology*, **2017**, 115, 455-461	2.8	32
702	Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 65.e19-25	2.8	32
701	Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. *European Urology*, **2012**, 61, 185-92	10.2	32
700	Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis. *BJU International*, **2012**, 109, 564-9	5.6	32

699	Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study. *BJU International*, **2012**, 109, 1155-61	5.6	32
698	Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 49.e7-14	2.8	32
697	Radical prostatectomy at academic versus nonacademic institutions: a population based analysis. *Journal of Urology*, **2011**, 186, 1849-54	2.5	32
696	Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. *Urology*, **2008**, 72, 1090-5	1.6	32
695	Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. *BJU International*, **2007**, 100, 528-32	5.6	32
694	Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 8.e17-8.e24	2.8	31
693	Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 230-42	2.8	31
692	Prediction of true nodal status in patients with pathological lymph node negative upper tract urothelial carcinoma at radical nephroureterectomy. *Journal of Urology*, **2013**, 189, 468-73	2.5	31
691	Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. *BJU International*, **2011**, 108, E304-9	5.6	31
690	Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. *BJU International*, **2008**, 101, 1362-7	5.6	31
689	Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. *Translational Andrology and Urology*, **2016**, 5, 735-744	2.3	31
688	Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. *World Journal of Urology*, **2020**, 38, 143-150	4	31
687	Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. *Journal of Urology*, **2002**, 167, 1475-81	2.5	31
686	Contemporary National Assessment of Robot-Assisted Surgery Rates and Total Hospital Charges for Major Surgical Uro-Oncological Procedures in the United States. *Journal of Endourology*, **2019**, 33, 438-447	2.7	30
685	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. *European Urology*, **2020**, 78, 661-669	10.2	30
684	Prospective external validation of a bladder cancer detection model. *Journal of Urology*, **2014**, 192, 1343-8	2.5	30
683	Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer. *Journal of Urology*, **2013**, 189, 1314-8	2.5	30
682	Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. *BJU International*, **2014**, 114, 56-61	5.6	30

681	Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma. *Journal of Urology*, **2014**, 191, 28-34	2.5	30
680	Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder. *European Urology*, **2014**, 65, 201-9	10.2	30
679	Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study. *Annals of Surgical Oncology*, **2012**, 19, 309-17	3.1	30
678	Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. *Urology*, **2003**, 61, 359-64	1.6	30
677	Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. *Reviews in Urology*, **2004**, 6, 58-72	1	30
676	Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. *European Urology*, **2020**, 78, 209-220	10.2	29
675	Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. *Prostate*, **2018**, 78, 469-475	4.2	29
674	The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. *European Urology Focus* , **2016**, 2, 79-85	5.1	29
673	Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. *Journal of Urology*, **2013**, 190, 487-92	2.5	29
672	Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: a population-based study. *Clinical Genitourinary Cancer*, **2015**, 13, e123-30	3.3	29
671	Conditional survival predictions after surgery for patients with penile carcinoma. *Cancer*, **2011**, 117, 3723-30	6.4	29
670	Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. *European Urology*, **2021**, 79, 44-53	10.2	29
669	Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract. *Journal of Urology*, **2015**, 193, 1486-93	2.5	28
668	Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 1166-71	2.8	28
667	The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 29.e13-20	2.8	28
666	Robot-assisted versus laparoscopic nephroureterectomy for upper-tract urothelial cancer: A population-based assessment of costs and perioperative outcomes. *Canadian Urological Association Journal*, **2014**, 8, E695-701	1.2	28
665	Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 433-40	2.8	28
664	A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis. *European Urology*, **2011**, 60, 1152-9	10.2	28

663	Clinical outcome of primary versus secondary bladder carcinoma in situ. *Journal of Urology*, **2010**, 184, 464-9	2.5	28
662	A NOVEL INTRAURETHRAL PROSTATIC BRIDGE CATHETER FOR PREVENTION OF TEMPORARY PROSTATIC OBSTRUCTION FOLLOWING HIGH ENERGY TRANSURETHRAL MICROWAVE THERMOTHERAPY IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. *Journal of Urology*, **1999**, 161, 144-151	2.5	28
661	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. *Cancer*, **2019**, 125, 1449-1458	6.4	28
660	A urinary microRNA (miR) signature for diagnosis of bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 531.e1-531.e8	2.8	28
659	Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. *World Journal of Urology*, **2017**, 35, 1541-1547	4	27
658	Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. *World Journal of Urology*, **2014**, 32, 999-1005	4	27
657	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. *World Journal of Urology*, **2013**, 31, 5-11	4	27
656	Impact of smoking on outcomes after intravesical bacillus Calmette-Guérin therapy for urothelial carcinoma not invading muscle of the bladder. *BJU International*, **2011**, 108, 526-30	5.6	27
655	Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. *Journal of Urology*, **2011**, 185, 1216-21	2.5	27
654	Response assessment using [Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. *Prostate*, **2020**, 80, 74-82	4.2	27
653	First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. *European Urology Oncology*, **2021**, 4, 755-765	6.7	27
652	Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. *European Urology*, **2018**, 73, 512-518	10.2	27
651	Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. *Cancer Research*, **2003**, 63, 5874-8	10.1	27
650	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. *World Journal of Urology*, **2017**, 35, 1401-1407	4	26
649	Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 71.e21-6	2.8	26
648	The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. *BJU International*, **2015**, 116, 72-8	5.6	26
647	Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. *European Urology Oncology*, **2018**, 1, 46-53	6.7	26
646	A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. *BJU International*, **2019**, 123, 11-21	5.6	26

645	The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. *World Journal of Urology*, **2014**, 32, 669-76	4	26
644	Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA. *BJU International*, **2012**, 109, 1807-12	5.6	26
643	Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time. *BJU International*, **2013**, 111, E283-9	5.6	26
642	Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma. *Urology*, **2011**, 77, 861-6	1.6	26
641	Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. *BJU International*, **2011**, 108, 502-7	5.6	26
640	A contemporary population-based assessment of the rate of lymph node dissection for penile carcinoma. *Annals of Surgical Oncology*, **2011**, 18, 439-46	3.1	26
639	Clinicians are most familiar with nomograms and rate their clinical usefulness highest, look-up tables are second best. *European Urology*, **2008**, 54, 958-9	10.2	26
638	Accuracy of life tables in predicting overall survival in candidates for radiotherapy for prostate cancer. *International Journal of Radiation Oncology Biology Physics*, **2007**, 69, 88-94	4	26
637	Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. *Urology*, **2006**, 68, 538-42	1.6	26
636	Female with bladder cancer: what and why is there a difference?. *Translational Andrology and Urology*, **2016**, 5, 668-682	2.3	26
635	Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey. *European Urology Focus*, **2019**, 5, 681-688	5.1	26
634	Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis. *JAMA Oncology*, **2018**, 4, 953-961	13.4	26
633	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. *World Journal of Urology*, **2017**, 35, 121-130	4	25
632	Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment. *Prostate*, **2017**, 77, 686-693	4.2	25
631	Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in peri-operative outcomes among selected centres in North America and Europe: an international multicentre collaboration. *BJU International*, **2019**, 124, 656	5.6	25
630	KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. *Future Oncology*, **2020**, 16, 507-516	3.6	25
629	Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making. *BJU International*, **2016**, 117, 272-9	5.6	25
628	Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 480-6	2.8	25

627	Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. *International Urology and Nephrology*, **2017**, 49, 2143-2149	2.3	25
626	Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. *Journal of Urology*, **2017**, 197, 287-295	2.5	25
625	Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. *Clinical Genitourinary Cancer*, **2017**, 15, e267-e273	3.3	25
624	Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer. *Current Opinion in Urology*, **2014**, 24, 492-9	2.8	25
623	Clinical outcome of standardized Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 713-720	8.8	25
622	Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. *European Urology Focus*, **2019**, 5, 488-496	5.1	25
621	Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. *World Journal of Urology*, **2020**, 38, 1165-1175	4	25
620	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer. *Clinical Genitourinary Cancer*, **2017**, 15, e755-e764	3.3	24
619	Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 430-436	2.8	24
618	In-hospital length of stay after major surgical oncological procedures. *European Journal of Surgical Oncology*, **2018**, 44, 969-974	3.6	24
617	Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. *BJU International*, **2013**, 111, 74-84	5.6	24
616	Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker. *Prostate*, **2015**, 75, 1760-7	4.2	24
615	Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. *Cancer Biology and Therapy*, **2014**, 15, 1239-47	4.6	24
614	Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis. *BJU International*, **2014**, 114, 503-10	5.6	24
613	Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. *International Journal of Radiation Oncology Biology Physics*, **2001**, 51, 16-22	4	24
612	Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder. *World Journal of Urology*, **2018**, 36, 231-240	4	24
611	First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. *BJU International*, **2018**, 121, 592-599	5.6	24
610	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. *World Journal of Urology*, **2017**, 35, 327-335	4	23

609	Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. *BJU International*, **2012**, 109, 685-90	5.6	23
608	Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. *Journal of Urology*, **2017**, 197, 580-589	2.5	23
607	Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract--is there evidence for discordant biology?. *Journal of Urology*, **2014**, 191, 926-31	2.5	23
606	Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. *World Journal of Urology*, **2012**, 30, 753-9	4	23
605	Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. *BJU International*, **2008**, 101, 561-5	5.6	23
604	Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. *Cancer Immunology, Immunotherapy*, **2021**, 70, 265-273	7.4	23
603	Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer. *European Urology*, **2015**, 68, 552-4	10.2	22
602	Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. *Journal of Urology*, **2015**, 194, 304-308	2.5	22
601	Comparison of complications from radical cystectomy between old-old versus oldest-old patients. *Urologia Internationalis*, **2015**, 94, 25-30	1.9	22
600	Management of bladder cancer in older patients: Position paper of a SIOG Task Force. *Journal of Geriatric Oncology*, **2020**, 11, 1043-1053	3.6	22
599	A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 293-305	2.8	22
598	Impact of ABO blood type on outcomes in patients with primary nonmuscle invasive bladder cancer. *Journal of Urology*, **2014**, 191, 1238-43	2.5	22
597	Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy?. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 27.e7-13	2.8	22
596	ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy. *Journal of Urology*, **2015**, 194, 1456-62	2.5	22
595	Predictors of survival in patients with soft tissue surgical margin involvement at radical cystectomy. *Annals of Surgical Oncology*, **2013**, 20, 1027-34	3.1	22
594	Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. *BJU International*, **2013**, 112, 623-37	5.6	22
593	Use of nomograms for predictions of outcome in patients with advanced bladder cancer. *Therapeutic Advances in Urology*, **2009**, 1, 13-26	3.2	22
592	Upper urinary tract disease: what we know today and unmet needs. *Translational Andrology and Urology*, **2015**, 4, 261-72	2.3	22

591	External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. *European Urology*, **2019**, 75, 319-328	10.2	22
590	First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).. *Journal of Clinical Oncology*, **2021**, 39, 391-391	2.2	22
589	Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. *Bladder Cancer*, **2018**, 4, 91-112	1	21
588	Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 239.e1-239.e7	2.8	21
587	Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages. *Prostate*, **2018**, 78, 753-757	4.2	21
586	Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. *European Urology*, **2014**, 66, 379-85	10.2	21
585	In-hospital mortality and failure-to-rescue rates after radical cystectomy. *BJU International*, **2013**, 112, E20-7	5.6	21
584	Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis. *BJU International*, **2014**, 113, 733-40	5.6	21
583	Effect of statin use on outcomes of non-muscle-invasive bladder cancer. *BJU International*, **2013**, 112, E4-12	5.6	21
582	The changing role of lasers in urologic surgery. *Current Opinion in Urology*, **2020**, 30, 24-29	2.8	21
581	Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. *European Urology Focus*, **2020**, 6, 1233-1239	5.1	21
580	3D T2-weighted imaging to shorten multiparametric prostate MRI protocols. *European Radiology*, **2018**, 28, 1634-1641	8	21
579	Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients. *Clinical Genitourinary Cancer*, **2017**, 15, e603-e607	3.3	20
578	Genetic determinants for chemo- and radiotherapy resistance in bladder cancer. *Translational Andrology and Urology*, **2017**, 6, 1081-1089	2.3	20
577	Oncologic Outcomes of Kidney Sparing Surgery versus Radical Nephroureterectomy for the Elective Treatment of Clinically Organ Confined Upper Tract Urothelial Carcinoma of the Distal Ureter. *Journal of Urology*, **2016**, 195, 1354-1361	2.5	20
576	Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. *BJU International*, **2013**, 111, 589-95	5.6	20
575	Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. *Urologia*, **2017**, 84, 9-19	1.2	20
574	Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 625-30	2.8	20

573	Smoking reduces the efficacy of intravesical bacillus Calmette-Guérin immunotherapy in non-muscle-invasive bladder cancer. *European Urology*, **2012**, 62, 1204-6	10.2	20
572	Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. *Urology Annals*, **2011**, 3, 119-26	1	20
571	PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer. *Memo - Magazine of European Medical Oncology*, **2018**, 11, 43-46	0.3	19
570	The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT non-metastatic renal cell carcinoma treated with radical nephrectomy. *BJU International*, **2018**, 121, 383-392	5.6	19
569	Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 167.e9-16	2.8	19
568	Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 233.e1-6	2.8	19
567	Prospective evaluation of the performance of [Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 2169-2177	8.8	19
566	Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma. *World Journal of Urology*, **2013**, 31, 31-6	4	19
565	Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T N M renal cell carcinoma. *World Journal of Urology*, **2017**, 35, 1899-1905	4	19
564	Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder. *Human Pathology*, **2011**, 42, 347-55	3.7	19
563	Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. *BJU International*, **2011**, 108, 687-92	5.6	19
562	Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 179.e19-179.e28	2.8	19
561	Postoperative nomogram for disease recurrence and cancer-specific death for upper tract urothelial carcinoma: comparison to American Joint Committee on Cancer staging classification. *Urology Journal*, **2014**, 11, 1435-41	0.9	19
560	Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patients. *BJU International*, **2015**, 115, 722-7	5.6	18
559	Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. *World Journal of Urology*, **2018**, 36, 1621-1627	4	18
558	A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. *Cancer Treatment Reviews*, **2016**, 48, 25-33	14.4	18
557	Pathologic nodal staging scores in patients treated with radical prostatectomy: a postoperative decision tool. *European Urology*, **2014**, 66, 439-46	10.2	18
556	Pelvic lymph node dissection for prostate cancer: adherence and accuracy of the recent guidelines. *International Journal of Urology*, **2013**, 20, 405-10	2.3	18

555	Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer. *World Journal of Urology*, **2012**, 30, 847-52	4	18
554	Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression. *BJU International*, **2011**, 108, 31-7	5.6	18
553	A critical assessment of the value of lymph node dissection at radical prostatectomy: A population-based study. *Prostate*, **2011**, 71, 1587-94	4.2	18
552	Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. *Journal of Urology*, **2007**, 178, 1229-36; discussion 1236-7	2.5	18
551	En bloc resection for nonmuscle invasive bladder cancer: review of the recent literature. *Current Opinion in Urology*, **2020**, 30, 41-47	2.8	18
550	Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. *International Journal of Clinical Oncology*, **2020**, 25, 1892-1900	4.2	18
549	Performance of [Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 1-10	6.2	18
548	The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. *European Urology*, **2021**, 79, 783-792	10.2	18
547	The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes. *European Urology Oncology*, **2019**, 2, 541-548	6.7	17
546	Comparison of perioperative complications and health-related quality of life between robot-assisted and open radical cystectomy: A systematic review and meta-analysis. *International Journal of Urology*, **2019**, 26, 760-774	2.3	17
545	Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 312.e9-312.e15	2.8	17
544	Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies. *Journal of Urology*, **2018**, 199, 1149-1157	2.5	17
543	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. *World Journal of Urology*, **2018**, 36, 7-13	4	17
542	Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality. *Clinical Genitourinary Cancer*, **2018**, 16, 376-384.e1	3.3	17
541	Current Disease Management of Primary Urethral Carcinoma. *European Urology Focus*, **2019**, 5, 722-734	5.1	17
540	Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma. *Urology*, **2014**, 84, 1134-40	1.6	17
539	Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 663-9	2.8	17
538	Sociodemographic disparities in the treatment of small renal masses. *BJU International*, **2013**, 111, E274-80	3.8	17

537	Survival after nephroureterectomy for upper tract urothelial carcinoma: a population-based competing-risks analysis. *International Journal of Urology*, **2014**, 21, 249-56	2.3	17
536	Predictors of survival in patients with disease recurrence after radical nephroureterectomy. *BJU International*, **2014**, 113, 911-7	5.6	17
535	Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years?. *Therapeutic Advances in Urology*, **2011**, 3, 69-80	3.2	17
534	Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. *Urologia Internationalis*, **2011**, 87, 42-8	1.9	17
533	Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. *BJU International*, **2008**, 101, 450-4	5.6	17
532	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of Ga-PSMA and C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. *Journal of Urology*, **2020**, 204, 296-302	2.5	17
531	Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study. *Canadian Urological Association Journal*, **2016**, 10, E82-6	1.2	17
530	Role of salvage lymph node dissection in prostate cancer. *Current Opinion in Urology*, **2016**, 26, 581-9	2.8	17
529	Development of a Preoperative Nomogram Incorporating Biomarkers of Systemic Inflammatory Response to Predict Nonorgan-confined Urothelial Carcinoma of the Bladder at Radical Cystectomy. *Urology*, **2016**, 95, 132-8	1.6	17
528	Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour. *BJU International*, **2019**, 123, 646-650	5.6	17
527	Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. *Archivos Espanoles De Urologia*, **2011**, 64, 681-94	0.4	17
526	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). *World Journal of Urology*, **2017**, 35, 251-259	4	16
525	Preoperative nomogram to predict the likelihood of complications after radical nephroureterectomy. *BJU International*, **2017**, 119, 268-275	5.6	16
524	The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer. *Translational Andrology and Urology*, **2019**, 8, 46-53	2.3	16
523	Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta. *World Journal of Urology*, **2015**, 33, 1945-50	4	16
522	Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 485.e7-485.e14	2.8	16
521	International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. *BJU International*, **2012**, 110, 674-81	5.6	16
520	Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy. *Surgical Oncology*, **2020**, 32, 8-13	2.5	16

519	Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. *European Urology*, **2020**, 77, 583-598	10.2	16
518	Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer. *Clinical Genitourinary Cancer*, **2019**, 17, e130-e139	3.3	16
517	Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. *European Urology Focus*, **2021**, 7, 124-131	5.1	16
516	Multiparametric MRI of the prostate at 3 T: limited value of 3D (1)H-MR spectroscopy as a fourth parameter. *World Journal of Urology*, **2016**, 34, 649-56	4	15
515	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. *World Journal of Urology*, **2017**, 35, 113-120	4	15
514	Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 264-271	2.8	15
513	Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy. *World Journal of Urology*, **2015**, 33, 1165-71	4	15
512	Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. *International Journal of Clinical Oncology*, **2020**, 25, 1037-1054	4.2	15
511	Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 256.e7-256.e13	2.8	15
510	Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. *European Urology Focus*, **2019**, 5, 807-814	5.1	15
509	Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC). *BJU International*, **2014**, 113, E62-6	5.6	15
508	Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. *Journal of Urology*, **2014**, 191, 830-41	2.5	15
507	Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma. *European Urology*, **2012**, 62, e27-9	10.2	15
506	Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy?. *Current Opinion in Urology*, **2015**, 25, 476-82	2.8	15
505	Leapfrog volume thresholds and perioperative complications after radical prostatectomy. *Cancer*, **2012**, 118, 4991-8	6.4	15
504	Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy. *Urology*, **2011**, 78, 1363-7	1.6	15
503	Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study. *Canadian Urological Association Journal*, **2012**, 6, 245-50	1.2	15
502	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 3.e17-3.e27	2.8	15

501	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. *European Urology Oncology*, **2021**, 4, 182-191	6.7	15
500	The interaction of gender and smoking on bladder cancer risks. *Current Opinion in Urology*, **2019**, 29, 249-255	2.8	15
499	Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. *European Urology Oncology*, **2019**, 2, 355-364	6.7	15
498	Quantitative Apparent Diffusion Coefficient Derived From Diffusion-Weighted Imaging Has the Potential to Avoid Unnecessary MRI-Guided Biopsies of mpMRI-Detected PI-RADS 4 and 5 Lesions. *Investigative Radiology*, **2018**, 53, 736-741	10.1	15
497	Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. *BJU International*, **2019**, 124, 738-745	5.6	14
496	Diagnosis and management of upper tract urothelial carcinoma. *Hematology/Oncology Clinics of North America*, **2015**, 29, 271-88, ix	3.1	14
495	Prognostic value of preoperative hematologic biomarkers in urothelial carcinoma of the bladder treated with radical cystectomy: a systematic review and meta-analysis. *International Journal of Clinical Oncology*, **2020**, 25, 1459-1474	4.2	14
494	Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 539-548	6.2	14
493	Robotic assisted simple prostatectomy: recent advances. *Current Opinion in Urology*, **2018**, 28, 309-314	2.8	14
492	Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 637-646	2.8	14
491	Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. *Clinical Genitourinary Cancer*, **2019**, 17, 409-418	3.3	14
490	Update on intravesical agents for non-muscle-invasive bladder cancer. *Immunotherapy*, **2010**, 2, 381-92	3.8	14
489	GENDER IS AN IMPORTANT PREDICTOR OF CANCER-SPECIFIC SURVIVAL IN PATIENT WITH TRANSITIONAL CELL CARCINOMA AFTER RADICAL CYSTECTOMY. *Journal of Urology*, **2009**, 181, 635	2.5	14
488	Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. *BJU International*, **2008**, 101, 1356-61	5.6	14
487	Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 372-379	2.8	14
486	External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival and Overall Survival following Radical Cystectomy. *Journal of Urology*, **2016**, 195, 283-9	2.5	13
485	North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer. *Prostate*, **2017**, 77, 542-548	4.2	13
484	The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 151.e17-151.e23	2.8	13

483	Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 315-333	2.8	13
482	Novel endoscopic visualization techniques for bladder cancer detection: a review of the contemporary literature. *Current Opinion in Urology*, **2018**, 28, 214-218	2.8	13
481	Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. *Urology*, **2016**, 94, 314.e1-7	1.6	13
480	The Moreau Strain of Bacillus Calmette-Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage?. *Urologia Internationalis*, **2016**, 96, 46-50	1.9	13
479	Impact of Perioperative Allogenic Blood Transfusion on Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. *Clinical Genitourinary Cancer*, **2016**, 14, 96-104	3.3	13
478	The impact of moderate wine consumption on the risk of developing prostate cancer. *Clinical Epidemiology*, **2018**, 10, 431-444	5.9	13
477	Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. *European Urology*, **2018**, 74, 693-696	10.2	13
476	Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 1716-24	2.8	13
475	Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. *World Journal of Urology*, **2012**, 30, 807-14	4	13
474	Biomarkers in personalised treatment of renal-cell carcinoma. *Lancet Oncology, The*, **2012**, 13, 751-2	21.7	13
473	Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. *Journal of Urology*, **2011**, 186, 2107-14	2.5	13
472	The treatment of muscle-invasive bladder cancer in geriatric patients. *Current Opinion in Urology*, **2016**, 26, 160-4	2.8	13
471	Quality Indicators for Bladder Cancer Services: A Collaborative Review. *European Urology*, **2020**, 78, 43-59	20.2	13
470	Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice?. *Current Opinion in Urology*, **2018**, 28, 577-583	2.8	13
469	Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. *European Journal of Surgical Oncology*, **2019**, 45, 1983-1992	3.6	12
468	Kidney-sparing surgery for upper tract urothelial cancer. *Current Opinion in Urology*, **2015**, 25, 100-4	2.8	12
467	Role of quantitative computed tomography texture analysis in the prediction of adherent perinephric fat. *World Journal of Urology*, **2018**, 36, 1635-1642	4	12
466	Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. *World Journal of Urology*, **2018**, 36, 639-644	4	12

465	Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≥80 years: a population-based study. *Prostate Cancer and Prostatic Diseases*, **2018**, 21, 71-77	6.2	12
464	Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma. *World Journal of Urology*, **2016**, 34, 1429-36	4	12
463	Construct, content and face validity of the camera handling trainer (CHT): a new E-BLUS training task for 30° laparoscope navigation skills. *World Journal of Urology*, **2016**, 34, 479-84	4	12
462	Highlights from the first symposium on upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 309-16	2.8	12
461	Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies. *International Journal of Radiation Oncology Biology Physics*, **2013**, 87, 960-7	4	12
460	Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA. *International Journal of Urology*, **2017**, 24, 117-123	2.3	12
459	Trends of retroperitoneal lymphadenectomy use in patients with nonseminomatous germ cell tumor of the testis: a population-based study. *Annals of Surgical Oncology*, **2011**, 18, 2997-3004	3.1	12
458	EVIDENCE-BASED GENDER RELATED OUTCOMES AFTER RADICAL CYSTECTOMY: RESULTS OF A LARGE MULTICENTER STUDY. *Journal of Urology*, **2009**, 181, 629	2.5	12
457	Carcinoma in situ of the upper urinary tract treated with radical nephroureterectomy--results from a multicenter study. *European Urology*, **2008**, 54, 961-3	10.2	12
456	Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept. *World Journal of Urology*, **2021**, 39, 3707-3709	4	12
455	Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma. *European Urology Oncology*, **2021**, 4, 792-801	6.7	12
454	Diagnostic Value of F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. *European Urology Oncology*, **2020**, 3, 73-79	6.7	12
453	Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy. *European Urology Oncology*, **2018**, 1, 169-175	6.7	12
452	High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. *Urologia Internationalis*, **2018**, 101, 7-15	1.9	12
451	Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study. *BJU International*, **2017**, 119, 234-238	5.6	11
450	Perioperative Allogenic Blood Transfusion in Renal Cell Carcinoma: Risk Factors and Effect on Long-term Outcomes. *Clinical Genitourinary Cancer*, **2017**, 15, e421-e427	3.3	11
449	Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma: results from a retrospective multicenter study. *World Journal of Urology*, **2015**, 33, 1005-13	4	11
448	A contemporary analysis of radiotherapy effect in surgically treated retroperitoneal sarcoma. *Radiotherapy and Oncology*, **2018**, 127, 318-325	5.3	11

447	Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. *World Journal of Urology*, **2018**, 36, 51-57	4	11
446	Dynamic Prognostication Using Conditional Recurrence and Progression Estimates for Patients with Nonmuscle Invasive Bladder Cancer. *Journal of Urology*, **2016**, 196, 46-51	2.5	11
445	The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis. *Canadian Urological Association Journal*, **2018**, 12, E325-E330	1.2	11
444	Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer. *Clinical Genitourinary Cancer*, **2018**, 16, e1123-e1132	3.3	11
443	A population-based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy. *BJU International*, **2012**, 109, 1177-82	5.6	11
442	Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent. *International Urology and Nephrology*, **2013**, 45, 1561-7	2.3	11
441	Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?. *World Journal of Urology*, **2017**, 35, 567-577	4	11
440	Systematic Review of the Impact of Testosterone Replacement Therapy on Depression in Patients with Late-onset Testosterone Deficiency. *European Urology Focus*, **2020**, 6, 170-177	5.1	11
439	Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis. *International Journal of Clinical Oncology*, **2020**, 25, 247-257	4.2	11
438	Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?. *Translational Andrology and Urology*, **2016**, 5, 702-710	2.3	11
437	Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature. *Translational Andrology and Urology*, **2016**, 5, 720-734	2.3	11
436	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in pT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. *International Journal of Radiation Oncology Biology Physics*, **2016**, 96, 333-340	4	11
435	The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 533.e1-533.e10	2.8	11
434	Rates of lymph node invasion and their impact on cancer specific mortality in upper urinary tract urothelial carcinoma. *European Journal of Surgical Oncology*, **2019**, 45, 1238-1245	3.6	11
433	More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. *Clinical Genitourinary Cancer*, **2019**, 17, 105-113.e2	3.3	11
432	Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients. *Journal of Geriatric Oncology*, **2020**, 11, 718-723	3.6	11
431	What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence. *Current Opinion in Urology*, **2018**, 28, 570-576	2.8	11
430	Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. *European Urology Oncology*, **2018**, 1, 314-320	6.7	11

429	Immune therapy meets precision medicine. *Lancet Oncology, The*, **2017**, 18, 271-273	21.7	10
428	Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 528.e1-528.e5	2.8	10
427	Postoperative paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population based analysis. *Surgical Oncology*, **2019**, 28, 201-207	2.5	10
426	Impact of Tumor Size on Cancer-Specific Mortality Rate After Local Tumor Ablation in T1a Renal-Cell Carcinoma. *Journal of Endourology*, **2019**, 33, 606-613	2.7	10
425	Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis. *World Journal of Urology*, **2019**, 37, 1557-1570	4	10
424	The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy. *World Journal of Urology*, **2015**, 33, 1769-76	4	10
423	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 495.e15-22	2.8	10
422	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical nephroureterectomy. *Journal of Surgical Oncology*, **2020**, 121, 688-696	2.8	10
421	Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. *Clinical Genitourinary Cancer*, **2018**, 16, 176-183	3.3	10
420	Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 81.e17-81.e24	2.8	10
419	Contemporary rates of adherence to international guidelines for pelvic lymph node dissection in radical cystectomy: a population-based study. *World Journal of Urology*, **2018**, 36, 1417-1422	4	10
418	Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 307.e9-307.e14	2.8	10
417	Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer. *Expert Review of Molecular Diagnostics*, **2018**, 18, 347-356	3.8	10
416	Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis. *Urology*, **2016**, 88, 97-103	1.6	10
415	Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis. *Anticancer Research*, **2019**, 39, 4357-4361	2.3	10
414	Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 1141-50	2.8	10
413	Predictors of cancer-specific mortality after disease recurrence in patients with squamous cell carcinoma of the penis. *European Urology*, **2014**, 66, 811-4	10.2	10
412	The importance of pelvic lymph node dissection in the elderly population: implications for interpreting the 2010 National Comprehensive Cancer Network practice guidelines for bladder cancer treatment. *Journal of Urology*, **2011**, 185, 2078-84	2.5	10

411	Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis. *Journal of Urology*, **2019**, 201, 46-53	2.5	10
410	Impact of Patients' Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis. *Clinical Genitourinary Cancer*, **2020**, 18, 88-94.e2	3.3	10
409	Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer. *Clinical Genitourinary Cancer*, **2020**, 18, 20-25.e2	3.3	10
408	Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 76.e1-76.e9	2.8	10
407	How to optimally manage elderly bladder cancer patients?. *Translational Andrology and Urology*, **2016**, 5, 683-691	2.3	10
406	The impact of gender on oncologic outcomes of bladder cancer. *Current Opinion in Urology*, **2019**, 29, 279-285	2.8	10
405	Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. *European Urology Focus*, **2019**, 5, 467-473	5.1	10
404	Nephroureterectomy with or without Bladder Cuff Excision for Localized Urothelial Carcinoma of the Renal Pelvis. *European Urology Focus*, **2020**, 6, 298-304	5.1	10
403	Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis. *World Journal of Urology*, **2020**, 38, 1437-1449	4	10
402	The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients. *European Urology Oncology*, **2018**, 1, 215-222	6.7	10
401	The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. *Urologia Internationalis*, **2018**, 101, 65-73	1.9	10
400	Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer. *Journal of Urology*, **2016**, 195, 1120-5	2.5	9
399	The effect of age and comorbidities on early postoperative complications after radical cystectomy: A contemporary population-based analysis. *Journal of Geriatric Oncology*, **2019**, 10, 623-631	3.6	9
398	Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need. *Current Treatment Options in Oncology*, **2019**, 20, 40	5.4	9
397	Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma. *Clinical Genitourinary Cancer*, **2019**, 17, e602-e611	3.3	9
396	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 573-580	6.2	9
395	Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. *World Journal of Urology*, **2018**, 36, 1399-1407	4	9
394	The impact of time to catheter removal on short-, intermediate- and long-term urinary continence after radical prostatectomy. *World Journal of Urology*, **2018**, 36, 1247-1253	4	9

393	Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence. *Clinical Genitourinary Cancer*, **2018**, 16, e903-e908	3.3	9
392	Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors. *Clinical Genitourinary Cancer*, **2019**, 17, e1026-e1035	3.3	9
391	Histologic variants of upper tract urothelial carcinoma do not affect response to adjuvant chemotherapy after radical nephroureterectomy. *European Urology*, **2012**, 62, e25-6	10.2	9
390	Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder. *BJU International*, **2012**, 110, 961-6	5.6	9
389	Association between Inflammatory Potential of Diet and Bladder Cancer Risk: Results of 3 United States Prospective Cohort Studies. *Journal of Urology*, **2019**, 202, 484-489	2.5	9
388	Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis. *Clinical Genitourinary Cancer*, **2020**, 18, 78-87	3.3	9
387	Enhanced Recovery after Radical Cystectomy. *Current Opinion in Urology*, **2019**, 29, 227-238	2.8	9
386	Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis?. *Cancer Epidemiology*, **2019**, 58, 83-88	2.8	9
385	Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. *European Urology Focus*, **2019**, 5, 381-388	5.1	9
384	Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 77.e1-77.e7	2.8	9
383	Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy. *Prostate Cancer and Prostatic Diseases*, **2018**, 21, 100-105	6.2	9
382	Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. *Cancer Epidemiology*, **2018**, 56, 118-125	2.8	9
381	Comparison of Perioperative Outcomes Between Open and Robotic Radical Cystectomy: A Population-Based Analysis. *Journal of Endourology*, **2018**, 32, 701-709	2.7	9
380	Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy. *Clinical Genitourinary Cancer*, **2017**, 15, e681-e688	3.3	8
379	Do Younger Patients with Muscle-Invasive Bladder Cancer have Better Outcomes?. *Journal of Clinical Medicine*, **2019**, 8,	5.1	8
378	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. *European Urology*, **2019**, 76, 443-449	10.2	8
377	Perioperative blood transfusion affects oncologic outcomes after nephrectomy for renal cell carcinoma: A systematic review and meta-analysis. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 273-281	2.8	8
376	Novel biomarkers to predict response and prognosis in localized bladder cancer. *Urologic Clinics of North America*, **2015**, 42, 225-33, ix	2.9	8

375	TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. *World Journal of Urology*, **2015**, 33, 1965-72	4	8
374	Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer. *Current Opinion in Urology*, **2020**, 30, 547-556	2.8	8
373	Where do urologists stand in the era of novel coronavirus-2019 disease. *Current Opinion in Urology*, **2020**, 30, 610-616	2.8	8
372	Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 602.e11-602.e19	2.8	8
371	Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram. *Prostate Cancer and Prostatic Diseases*, **2018**, 21, 386-393	6.2	8
370	Neoadjuvant and adjuvant treatment in high-risk prostate cancer. *Expert Review of Clinical Pharmacology*, **2018**, 11, 425-438	3.8	8
369	Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 158.e1-158.e6	2.8	8
368	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. *European Urology*, **2018**, 74, 134-137	10.2	8
367	Cost analysis of prostate cancer detection including the prostate health index (phi). *World Journal of Urology*, **2019**, 37, 481-487	4	8
366	The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 659-671	2.8	8
365	Words of wisdom: re: a prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. *European Urology*, **2013**, 63, 399-400	10.2	8
364	Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. *World Journal of Urology*, **2017**, 35, 1073-1080	4	8
363	Collaborative research networks as a platform for virtual multidisciplinary, international approach to managing difficult clinical cases: an example from the Upper Tract Urothelial Carcinoma Collaboration. *European Urology*, **2012**, 62, 943-5	10.2	8
362	Genomics: a preview of genomic medicine. *BJU International*, **2008**, 102, 1221-7	5.6	8
361	Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder. *Translational Andrology and Urology*, **2017**, 6, 1018-1026	2.3	8
360	A review of thulium-fiber laser in stone lithotripsy and soft tissue surgery. *Current Opinion in Urology*, **2020**, 30, 853-860	2.8	8
359	The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients. *Prostate*, **2021**, 81, 339-346	4.2	8
358	Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. *International Journal of Urology*, **2021**, 28, 862-869	2.3	8

357	Comparison of perioperative outcomes between open and minimally invasive nephroureterectomy: A population-based analysis. *International Journal of Urology*, **2019**, 26, 487-492	2.3	8
356	Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 179.e1-179.e7	2.8	8
355	Regional differences in total hospital charges between open and robotically assisted radical prostatectomy in the United States. *World Journal of Urology*, **2019**, 37, 1305-1313	4	8
354	A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. *European Urology Focus*, **2019**, 5, 449-456	5.1	8
353	Prediction of response and survival after standardized treatment with 7400´MBq Lu-PSMA-617 every 4´weeks in patients with metastatic castration-resistant prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 1650-1657	8.8	8
352	Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. *Cancer Epidemiology*, **2018**, 54, 112-118	2.8	8
351	Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 460.e1-460.e8	2.8	7
350	Role of lasers in urology. *Photochemical and Photobiological Sciences*, **2019**, 18, 295-303	4.2	7
349	The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy. *Surgical Oncology*, **2019**, 28, 208-213	2.5	7
348	Intravesical bacillus Calmette-Guﬃn for bladder cancer: are all the strains equal?. *Translational Andrology and Urology*, **2019**, 8, 85-93	2.3	7
347	Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis. *European Urology Oncology*, **2021**, 4, 580-593	6.7	7
346	Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 774-782	2.8	7
345	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 639.e1-639.e9	2.8	7
344	Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer. *Clinical Genitourinary Cancer*, **2017**,	3.3	7
343	Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. *World Journal of Urology*, **2016**, 34, 1411-9	4	7
342	Diagnosis and kidney-sparing treatments for upper tract urothelial carcinoma: state of the art. *Minerva Urology and Nephrology*, **2018**, 70, 242-251	2.3	7
341	The Effect of Institution Teaching Status on Perioperative Outcomes After Robotic Partial or Radical Nephrectomy. *Journal of Endourology*, **2018**, 32, 621-629	2.7	7
340	Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer. *Urologia Internationalis*, **2018**, 101, 197-200	1.9	7

339	The evolving role of percutaneous biopsy in renal masses. *Current Opinion in Urology*, **2018**, 28, 364-368	2.8	7
338	Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature. *European Urology Oncology*, **2018**, 1, 283-291	6.7	7
337	Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. *Journal of Clinical Medicine*, **2019**, 8,	5.1	7
336	Contemporary gender-specific outcomes in Germany after radical cystectomy for bladder cancer. *Current Urology Reports*, **2014**, 15, 409	2.9	7
335	Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 47.e1-8	2.8	7
334	The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence?. *World Journal of Urology*, **2013**, 31, 1369-76	4	7
333	Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. *Clinical Genitourinary Cancer*, **2017**, 15, e1039-e1045	3.3	7
332	Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. *Bladder Cancer*, **2017**, 3, 161-169	1	7
331	Hospital and surgical caseload are predictors of comprehensive surgical treatment for bladder cancer: a population based study. *Journal of Urology*, **2011**, 186, 824-8	2.5	7
330	Management of upper urinary tract urothelial carcinoma. *Expert Review of Anticancer Therapy*, **2010**, 10, 1955-65	3.5	7
329	Prognostic value of cyclooxygenase-2 expression in squamous cell carcinoma of the bladder. *Journal of Urology*, **2011**, 185, 1112-7	2.5	7
328	COMBINATION OF CELL CYCLE REGULATING BIO-MARKERS IMPROVES PROGNOSIS IN PATIENTS WITH ORGAN CONFINED UROTHELIAL CANCER AT RADICAL CYSTECTOMY. *Journal of Urology*, **2008**, 179, 578-578	2.5	7
327	Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. *Biomarkers in Medicine*, **2008**, 2, 165-80	2.3	7
326	Pathomics in urology. *Current Opinion in Urology*, **2020**, 30, 823-831	2.8	7
325	Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. *BJU International*, **2021**, 128, 79-87	5.6	7
324	Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. *European Urology Oncology*, **2021**, 4, 170-179	6.7	7
323	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. *BJU International*, **2021**,	5.6	7
322	First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. *European Journal of Cancer*, **2021**, 151, 35-48	7.5	7

321	Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. *Expert Review of Molecular Diagnostics*, **2016**, 16, 1189-1199	3.8	7
320	Primary Ta high grade bladder tumors: Determination of the risk of progression. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 132.e7-132.e11	2.8	7
319	Prostate biopsy: guidelines and evidence. *Current Opinion in Urology*, **2018**, 28, 354-359	2.8	7
318	Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 409-421	2.8	7
317	Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?. *World Journal of Urology*, **2016**, 34, 105-12	4	6
316	External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 33.e21-33.e26	2.8	6
315	Reply to Harry Herr© Letter to the Editor re: Marko Babjuk, Andreas Böhle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71:447-61. *European Urology*, **2017**, 71, e173-e174	10.2	6
314	Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. *International Urology and Nephrology*, **2019**, 51, 2181-2188	2.3	6
313	Impact of alcohol consumption on the risk of developing bladder cancer: a systematic review and meta-analysis. *World Journal of Urology*, **2019**, 37, 2313-2324	4	6
312	Histopathology and prognosis of de novo bladder tumors following solid organ transplantation. *World Journal of Urology*, **2015**, 33, 2087-93	4	6
311	Stratification of Intermediate-risk Non-muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies. *European Urology Focus*, **2021**, 7, 566-573	5.1	6
310	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. *European Urology*, **2020**, 78, 779-782	10.2	6
309	Treatment trends and Medicare reimbursements for localized prostate cancer in elderly patients. *Canadian Urological Association Journal*, **2018**, 12, E338-E344	1.2	6
308	Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy. *Clinical Genitourinary Cancer*, **2019**, 17, e1153-e1162	3.3	6
307	Comprehensive handbook for developing a bladder cancer cystectomy database. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 812-26	2.8	6
306	Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study. *European Journal of Surgical Oncology*, **2017**, 43, 2193-2199	3.6	6
305	The effect of age on bladder cancer incidence, prognosis and therapy. *Aging Health*, **2010**, 6, 649-659		6
304	Assessment of local tumor ablation and non-interventional management versus partial nephrectomy in T1a renal cell carcinoma. *Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology*, **2020**, 72, 350-359	4.4	6

303	E-CADHERIN IMMUNOSTAINING OF BLADDER TRANSITIONAL CELL CARCINOMA, CARCINOMA IN SITU AND LYMPH NODE METASTASES WITH LONG-TERM FOLLOWUP. *Journal of Urology*, **2001**, 1473-1479	2.5	6
302	Role of cigarette smoking in urological malignancies and clinical interventions for smoking cessation. *Central European Journal of Urology*, **2016**, 69, 366-369	0.9	6
301	Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 180-190	2.8	6
300	Risk stratification for kidney sparing procedure in upper tract urothelial carcinoma. *Translational Andrology and Urology*, **2016**, 5, 711-719	2.3	6
299	Salvage therapeutic strategies for bacillus Calmette-Guerin failure. *Current Opinion in Urology*, **2019**, 29, 239-246	2.8	6
298	The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer. *World Journal of Urology*, **2019**, 37, 1127-1135	4	6
297	Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization. *World Journal of Urology*, **2020**, 38, 121-128	4	6
296	Conditional survival of patients with stage I-III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. *World Journal of Urology*, **2020**, 38, 725-732	4	6
295	Catalog of exogenous risk factors for bladder carcinogenesis. *Current Opinion in Urology*, **2020**, 30, 449-456	2.8	6
294	Intravesical therapy for bladder cancer in the pandemic of Covid-19. *World Journal of Urology*, **2021**, 39, 1313-1314	4	6
293	Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder. *European Journal of Surgical Oncology*, **2021**, 47, 463-469	3.6	6
292	Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities. *Clinical Genitourinary Cancer*, **2021**, 19, 60-68.e1	3.3	6
291	The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 236.e1-236.e7	2.8	6
290	Intermediate and long-term complications associated with adjuvant chemotherapy for stage I germ cell tumor patients. *Current Opinion in Urology*, **2018**, 28, 485-490	2.8	6
289	Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. *BJU International*, **2021**,	5.6	6
288	Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. *Cancer Treatment Reviews*, **2021**, 99, 102242	14.4	6
287	Tissue-based molecular markers for bladder cancer. *Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology*, **2010**, 62, 241-58	4.4	6
286	Urothelial cancer of the upper urinary tract: emerging biomarkers and integrative models for risk stratification. *Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology*, **2016**, 68, 381-95	4.4	6

285	Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 113.e9-113.e14	2.8	5
284	Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis. *BJU International*, **2019**, 124, 1006-1013	5.6	5
283	Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma as a Prognostic Factor after Radical Prostatectomy: A Systematic Review and Meta-Analysis. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	5
282	Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 601.e17-601.e24	2.8	5
281	Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. *Cancer Causes and Control*, **2020**, 31, 263-272	2.8	5
280	Ureteral and urethral recurrence after radical cystectomy: a systematic review. *Current Opinion in Urology*, **2020**, 30, 441-448	2.8	5
279	HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas. *Pathology and Oncology Research*, **2018**, 24, 575-581	2.6	5
278	How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 893-899	2.8	5
277	Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer. *Clinical Genitourinary Cancer*, **2019**, 17, e939-e945	3.3	5
276	Impact of statin use on oncologic outcomes of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. *European Urology*, **2013**, 63, 1134-5	10.2	5
275	Analysis of hematological parameters as prognostic markers for toxicity and survival of Radium treatment. *Oncotarget*, **2018**, 9, 16197-16204	3.3	5
274	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. *European Urology Oncology*, **2021**,	6.7	5
273	Metastasis-directed therapy and prostate-targeted therapy in oligometastatic prostate cancer: a systematic review. *Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology*, **2020**, 72, 531-542	4.4	5
272	Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. *Current Opinion in Urology*, **2020**, 30, 701-710	2.8	5
271	The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC). *Clinical Genitourinary Cancer*, **2021**, 19, 272.e1-272.e7	3.3	5
270	Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer. *Cells*, **2020**, 9,	7.9	5
269	Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma. *Clinical Genitourinary Cancer*, **2021**, 19, 117-124	3.3	5
268	Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized trials. *BJU International*, **2021**, 128, 280-289	5.6	5

267	Intracorporeal versus extracorporeal urinary diversion in robot-assisted radical cystectomy: a systematic review and meta-analysis. *International Journal of Clinical Oncology*, **2021**, 26, 1587-1599	4.2	5
266	Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. *Bladder Cancer*, **2016**, 2, 91-99	1	5
265	Role of serum cholinesterase in patients treated with salvage radical prostatectomy. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 123-129	2.8	5
264	Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma. *Clinical Genitourinary Cancer*, **2019**, 17, e97-e103	3.3	5
263	Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study. *Clinical Genitourinary Cancer*, **2019**, 17, 72-78.e4	3.3	5
262	Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. *Cancer Immunology, Immunotherapy*, **2021**, 70, 2641-2650	7.4	5
261	North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients. *British Journal of Cancer*, **2018**, 119, 1552-1556	8.7	5
260	Tissue biomarkers in nonmuscle-invasive bladder cancer: any role in clinical practice?. *Current Opinion in Urology*, **2018**, 28, 584-590	2.8	5
259	Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA subtype project). *Scandinavian Journal of Urology*, **2017**, 51, 269-276	1.6	4
258	Characterization of Late Recurrence After Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients. *Urology*, **2017**, 106, 119-124	1.6	4
257	The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder. *Journal of Surgical Oncology*, **2019**, 120, 1266-1275	2.8	4
256	Re: Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Carcinoma (PURE-01): An Open-label, Single-arm, Phase II Study. *European Urology*, **2019**, 75, 695-696	10.2	4
255	Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?. *Urologia Internationalis*, **2019**, 102, 269-276	1.9	4
254	Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria. *Oncology Letters*, **2019**, 18, 57-62	2.6	4
253	Risk stratification of upper tract urothelial carcinoma: A Review of the Current Literature. *Expert Review of Anticancer Therapy*, **2019**, 19, 503-513	3.5	4
252	Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 702-710	2.8	4
251	Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy. *European Journal of Surgical Oncology*, **2019**, 45, 1253-1259	3.6	4
250	Association of Processed Meats and Alcohol Consumption with Renal Cell Carcinoma: A Worldwide Population-Based Study. *Nutrition and Cancer*, **2020**, 1-6	2.8	4

249	Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. *Clinical Genitourinary Cancer*, **2020**, 18, e730-e738	3.3	4
248	Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?. *Current Opinion in Urology*, **2020**, 30, 584-593	2.8	4
247	Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. *Journal of Surgical Oncology*, **2020**, 121, 1154-1161	2.8	4
246	The impact of hormones and reproductive factors on the risk of bladder cancer in women: results from the Nurses'Health Study and Nurses'Health Study II. *International Journal of Epidemiology*, **2020**, 49, 599-607	7.8	4
245	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. *World Journal of Urology*, **2016**, 34, 1155-61	4	4
244	Progressive tissue biomarker profiling in non-muscle-invasive bladder cancer. *Expert Review of Anticancer Therapy*, **2018**, 18, 695-703	3.5	4
243	Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. *World Journal of Urology*, **2019**, 37, 165-172	4	4
242	Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 578.e11-578.e19	2.8	4
241	Comprehensive analysis of in-hospital delirium after major surgical oncology procedures: A population-based study. *Canadian Urological Association Journal*, **2020**, 14, E84-E93	1.2	4
240	Re: Global effects of smoking, of quitting, and of taxing tobacco. *European Urology*, **2014**, 66, 176-8	10.2	4
239	Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. *Clinical Genitourinary Cancer*, **2017**, 15, e223-e228	3.3	4
238	Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy. *European Urology Focus*, **2015**, 1, 75-81	5.1	4
237	Prostate cancer risk estimation tool use by members of the American Urological Association: a survey based study. *Journal of Urology*, **2015**, 193, 1933-7	2.5	4
236	Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole	10.2	4
235	Keynote-676: Phase 3 study of bacillus calmette-guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction.. *Journal of Clinical Oncology*, **2019**, 37, TPS502-TPS502	2.2	4
234	Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. *Minerva Urology and Nephrology*, **2021**, 73, 610-615	2.3	4
233	Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes.. *Critical Reviews in Oncology/Hematology*, **2021**, 169, 103570	7	4
232	Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. *Clinical Genitourinary Cancer*, **2020**, 18, e402-e409	3.3	4

231	Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC). *World Journal of Urology*, **2021**, 39, 1961-1968	4	4
230	The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 785.e11-785.e17	2.8	4
229	Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis. *Cancers*, **2021**, 13,	6.6	4
228	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. *World Journal of Urology*, **2019**, 37, 2419-2427	4	4
227	Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract. *World Journal of Urology*, **2019**, 37, 1329-1337	4	4
226	Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis. *World Journal of Urology*, **2020**, 38, 1535-1544	4	4
225	The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. *World Journal of Urology*, **2021**, 39, 443-451	4	4
224	Obesity is associated with adverse short-term perioperative outcomes in patients treated with open and robot-assisted radical cystectomy for bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 75.e17-75.e25	2.8	4
223	Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media?. *European Radiology*, **2021**, 31, 3754-3764	8	4
222	Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis. *Arab Journal of Urology Arab Association of Urology*, **2020**, 19, 31-36	1.7	4
221	Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?. *European Urology Focus*, **2018**, 4, 525-528	5.1	4
220	Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer. *BJU International*, **2018**, 122, 695-704	5.6	4
219	Surgically Treated Retroperitoneal Sarcoma: A Population-based Competing Risks Analysis. *European Urology Oncology*, **2018**, 1, 346-351	6.7	4
218	Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 774-783	2.8	3
217	Contemporary trends of pelvic lymph node dissection at radical cystectomy for urothelial carcinoma of urinary bladder and associated cancer specific mortality and complications: comparison between octogenarian versus younger patients. *Cancer Epidemiology*, **2019**, 59, 135-142	2.8	3
216	Bladder sparing landscape for bacillus Calmette-Guﬁn unresponsive bladder cancer. *Current Opinion in Urology*, **2020**, 30, 542-546	2.8	3
215	The role of taxane-based chemotherapy in the treatment of prostate cancer. *Current Opinion in Urology*, **2020**, 30, 527-533	2.8	3
214	Safety and Short-Term Oncological Outcomes of Thulium Fiber Laser En Bloc Resection of Non-Muscle-Invasive Bladder Cancer: A Prospective Non-Randomized Phase II Trial. *Bladder Cancer*, **2020**, 6, 201-210	1	3

213	Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer. *Scandinavian Journal of Urology*, **2020**, 54, 52-57	1.6	3
212	Differences in short-term outcomes between open versus robot-assisted radical cystectomy in frail malnourished patients. *European Journal of Surgical Oncology*, **2020**, 46, 1347-1352	3.6	3
211	Oncologic outcomes after minimally invasive surgery for cT1 renal masses: a comprehensive review. *Current Opinion in Urology*, **2018**, 28, 132-138	2.8	3
210	Non-Muscle-Invasive Bladder Cancer in the Elderly Patient. *Current Geriatrics Reports*, **2014**, 3, 42-47	1.3	3
209	Segmental ureterectomy for upper tract urothelial carcinoma: two procedures with different indications. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 1841-3	2.8	3
208	Urothelial carcinoma at the uretero-enteric junction: multi-center evaluation of oncologic outcomes after radical nephroureterectomy. *Urologic Oncology: Seminars and Original Investigations* , **2013**, 31, 676-81	2.8	3
207	Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 672.e1-672.e6	2.8	3
206	Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. *Journal of Urology*, **2017**, 198, 1269-1277	2.5	3
205	Rectal preparation significantly improves prostate imaging quality: Assessment of the PI-QUAL score with visual grading characteristics.. *European Journal of Radiology*, **2022**, 147, 110145	4.7	3
204	ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder. *Anticancer Research*, **2017**, 37, 5747-5753	2.3	3
203	Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. *Clinical Genitourinary Cancer*, **2020**, 18, 117-128.e5	3.3	3
202	Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. *World Journal of Urology*, **2021**, 39, 2567-2577	4	3
201	Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages-A SEER-based Study. *European Urology Focus*, **2021**, 7, 1332-1338	5.1	3
200	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial	2.5	3
199	The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2020**, 43, 567-574	2.7	3
198	Smoking and bladder cancer: review of the recent literature. *Current Opinion in Urology*, **2020**, 30, 720-725	2.8	3
197	What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature. *Current Opinion in Urology*, **2021**, 31, 276-284	2.8	3
196	Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis. *European Urology Focus*, **2021**,	5.1	3

195	Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?. *Current Opinion in Urology*, **2021**, 31, 270-275	2.8	3
194	Novel transurethral resection technologies and training modalities in the management of nonmuscle invasive bladder cancer: a comprehensive review. *Current Opinion in Urology*, **2021**, 31, 324-331	2.8	3
193	Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. *Clinical Genitourinary Cancer*, **2019**, 17, e541-e548	3.3	3
192	4D perfusion CT of prostate cancer for image-guided radiotherapy planning: A proof of concept study. *PLoS ONE*, **2019**, 14, e0225673	3.7	3
191	Impact of Age on Perioperative Outcomes at Radical Prostatectomy: A Population-Based Study. *European Urology Focus*, **2020**, 6, 1213-1219	5.1	3
190	Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. *Clinical Genitourinary Cancer*, **2020**, 18, e610-e618	3.3	3
189	Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study. *World Journal of Urology*, **2021**, 39, 813-822	4	3
188	The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis. *BJU International*, **2021**, 127, 143-152	5.6	3
187	The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 15-33	2.8	3
186	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 235.e5-235.e14	2.8	3
185	Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. *BJU International*, **2021**, 127, 617-625	5.6	3
184	Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. *World Journal of Urology*, **2021**, 39, 3345-3352	4	3
183	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. *Translational Andrology and Urology*, **2021**, 10, 609-619	2.3	3
182	Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aN0M0 Renal Cell Carcinoma Patients. *European Urology Focus*, **2021**,	5.1	3
181	Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder. *Journal of Clinical Pathology*, **2021**,	3.9	3
180	Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer. *World Journal of Urology*, **2021**, 39, 3337-3344	4	3
179	Focal therapy of prostate cancer. *Current Opinion in Urology*, **2018**, 28, 550-554	2.8	3
178	Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 528.e7-528.e13	2.8	3

177	Molecularly-driven precision medicine for advanced bladder cancer. *World Journal of Urology*, **2018**, 36, 1749-1757	4	3
176	Partial nephrectomy in frail patients: Benefits of robot-assisted surgery. *Surgical Oncology*, **2021**, 38, 101588	2.5	3
175	Vesical Imaging Reporting and Data System (VI-RADS): Are the individual MRI sequences equivalent in diagnostic performance of high grade NMIBC and MIBC?. *European Journal of Radiology*, **2021**, 142, 109829	4.7	3
174	Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study. *International Journal of Urology*, **2021**, 28, 1247-1252	2.3	3
173	Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 356-362	2.8	2
172	A preoperative nomogram to predict major complications after robot assisted partial nephrectomy (UroCCR-57 study). *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 577.e1-577.e7	2.8	2
171	Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy. *Clinical Genitourinary Cancer*, **2019**, 17, e793-e801	3.3	2
170	The clinical pharmacology of the medical treatment for overactive bladder in adults. *Expert Review of Clinical Pharmacology*, **2020**, 13, 707-720	3.8	2
169	Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 537-544	2.8	2
168	Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 238.e19-238.e27	2.8	2
167	Oncologic Effect of Cumulative Smoking Exposure in Patients Treated With Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer. *Clinical Genitourinary Cancer*, **2018**, 16, e619-e627	2.3	2
166	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 343.e1-343.e8	2.8	2
165	Words of wisdom. Re: radical prostatectomy or watchful waiting in early prostate cancer. *European Urology*, **2014**, 66, 386-7	10.2	2
164	Gender Differences in Bladder and Kidney Cancers **2017**, 603-610		2
163	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. *Minerva Urology and Nephrology*, **2021**,	2.3	2
162	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. *Minerva Urology and Nephrology*, **2021**,	2.3	2
161	Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients.. *World Journal of Urology*, **2022**, 1	4	2
160	Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. *World Journal of Urology*, **2021**, 1	4	2

159	Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder: A Population-based Competing-risks Analysis Across Disease Stages. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2020**, 43, 880-888	2.7	2
158	Evaluation of Patterns of Presentation, Practice, and Outcomes of Upper Tract Urothelial Cancer: Protocol for an Observational, International, Multicenter, Cohort Study by the Clinical Research Office of the Endourology Society. *JMIR Research Protocols*, **2020**, 9, e15363	2	2
157	Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 260-268	6.2	2
156	Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. *Clinical Genitourinary Cancer*, **2020**, 18, 35-44.e1	3.3	2
155	PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 496-505	2.8	2
154	Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. *European Urology Focus*, **2021**, 7, 1067-1074	5.1	2
153	Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 936.e7-936.e14	2.8	2
152	Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 851.e19-851.e25	2.8	2
151	Aristolochic acid and its effect on different cancers in uro-oncology. *Current Opinion in Urology*, **2020**, 30, 689-695	2.8	2
150	Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. *European Urology Focus*, **2021**,	5.1	2
149	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. *Cancer Immunology, Immunotherapy*, **2021**, 1	7.4	2
148	The prognostic value of sarcopenia in patients with prostate cancer: a systematic review. *Current Opinion in Urology*, **2021**, 31, 315-323	2.8	2
147	The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. *Advances in Anatomic Pathology*, **2021**, 28, 196-208	5.1	2
146	Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. *World Journal of Urology*, **2021**, 39, 4355-4361	4	2
145	Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients. *Prostate*, **2021**, 81, 1055-1063	4.2	2
144	The effect of race on stage at presentation and survival in upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 788.e7-788.e13	2.8	2
143	Transfer of Knowledge in Urology: A Case Study of Jacob Eduard Polak (1818-1891) and the Introduction of Contemporary Techniques of Lithotomy and Lithotripsy from Vienna to Persia in the Mid-19th Century: A New Analysis of Scientific Papers from the 19th Century. *Urologia Internationalis*, **2019**, 102, 1-12	1.9	2
142	Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. *European Urology Focus*, **2019**, 5, 97-103	5.1	2

141	What Is Better for Predicting Morbidity of Robotic Partial Nephrectomy-A Score or Your Clinical Judgement?. *European Urology Focus*, **2020**, 6, 313-319	5.1	2
140	Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes. *Clinical Genitourinary Cancer*, **2020**, 18, 129-137.e3	3.3	2
139	Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. *OncoTargets and Therapy* , **2021**, 14, 315-324	4.4	2
138	Sex- and age-related differences in the distribution of bladder cancer metastases. *Japanese Journal of Clinical Oncology*, **2021**, 51, 976-983	2.8	2
137	Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 89.e1-89.e5	2.8	2
136	Risk factors associated with positive surgical margins location at radical cystectomy and their impact on bladder cancer survival. *World Journal of Urology*, **2021**, 39, 4363-4371	4	2
135	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. *World Journal of Urology*, **2021**, 39, 4345-4354	4	2
134	Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 471-479	2.8	2
133	Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. *Cancer Causes and Control*, **2021**, 1	2.8	2
132	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. *Molecular Carcinogenesis*, **2022**, 61, 5-18	5	2
131	Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. *European Urology*, **2021**, 80, 507-515	10.2	2
130	Adherent perinephric fat affects perioperative outcomes after partial nephrectomy: a systematic review and meta-analysis. *International Journal of Clinical Oncology*, **2021**, 26, 636-646	4.2	2
129	Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy.. *Cancers*, **2022**, 14,	6.6	2
128	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.. *Urologic Oncology: Seminars and Original Investigations*, **2021**,	2.8	2
127	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.. *Annals of Surgical Oncology*, **2022**, 1	3.1	2
126	Reply to Nicholas G. Zaorsky, Daniel E. Spratt, and Pierre Blanchard© Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28. *European Urology*, **2019**, 75, e98-e99	10.2	1
125	Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis. *European Urology Focus*, **2021**, 7, 1143-1156	5.1	1
124	Association of Prostate Cancer with Nuts, Seeds, Alcohol and Processed Meats: A Worldwide Population-Based Study. *Nutrition and Cancer*, **2020**, 1-8	2.8	1

123	Adherence to guideline recommendations for multimodality treatment of patients with pT2-3 M0 non-urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes. *International Journal of Urology*, **2020**, 27, 402-407	2.3	1
122	Rates of other-cause mortality after radical cystectomy are decreasing over time-A population-based analysis over two decades. *Journal of Surgical Oncology*, **2020**, 121, 1329-1336	2.8	1
121	Novel technologies that change the diagnostic and treatment paradigm in urology: En-bloc as the new treatment standard. *Current Opinion in Urology*, **2020**, 30, 475-476	2.8	1
120	External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: A´Population-based Study. *Clinical Genitourinary Cancer*, **2017**,	3.3	1
119	Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer. *Clinical Genitourinary Cancer*, **2019**, 17, 389-394	3.3	1
118	Incorporating biomarker research in a real-world setting: challenges of a prophecy. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 219-21	2.8	1
117	Does low-risk prostate cancer detection change with repeat biopsies?. *European Urology*, **2012**, 61, 230-1	10.2	1
116	Oncologic outcomes and survival in pT0 tumors after radical nephroureterectomy for upper tract urothelial carcinoma: results from of a large multicenter international collaborative study. *European Urology*, **2013**, 63, 404-5	10.2	1
115	Blood-Based Tumor Markers for Prostate Cancer **2013**, 73-84		1
114	Words of wisdom: Re: Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group trial. *European Urology*, **2013**,	10.2	1
113	The effect of AB0 and Rhesus blood grouping systems on oncological outcome in patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 671.e17-671.e23	2.8	1
112	MP58-04 DENSE DOSE MVAC VERSUS GC IN PATIENTS WITH CT3-4A BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: A REAL WORLD EXPERIENCE. *Journal of Urology*, **2017**, 197,	2.5	1
111	Words of wisdom. Re: Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML. J Urol 2008;179:1830-7; discussion 1837. *European Urology*, **2009**, 55, 245-6	10.2	1
110	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. *European Urology Focus*, **2021**,	5.1	1
109	Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis.. *Scandinavian Journal of Urology*, **2022**, 1-9	1.6	1
108	Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 40, 106.e11-106.e11	2.8	1
107	Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients. *International Urology and Nephrology*, **2021**, 54, 81	2.3	1
106	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer.. *Journal of Cancer Research and Clinical Oncology*, **2022**, 1	4.9	1

105	A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. *Minerva Urology and Nephrology*, **2022**, 74,	2.3	1
104	Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis and Network Meta-Analysis with Focus on Different Energy Sources. *Journal of Endourology*, **2021**,	2.7	1
103	Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients. *Prostate*, **2022**, 82, 120-131	4.2	1
102	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 685.e17-685.e25	2.8	1
101	Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. *World Journal of Urology*, **2021**, 39, 1947-1953	4	1
100	Incidence and preoperative predictors for major complications following radical nephroureterectomy. *Translational Andrology and Urology*, **2020**, 9, 1786-1793	2.3	1
99	Risk stratification for upper tract urinary carcinoma. *Translational Andrology and Urology*, **2020**, 9, 1799-1808	2.3	1
98	An up-to-date catalogue of urinary markers for the management of prostate cancer. *Current Opinion in Urology*, **2020**, 30, 684-688	2.8	1
97	Surgical intervention in patients with urothelial carcinoma of the bladder and lymph node metastasis. *Current Opinion in Urology*, **2021**, 31, 220-225	2.8	1
96	Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients. *European Urology Focus*, **2021**, 7, 598-607	5.1	1
95	Response and Toxicity to the Second Course of 3 Cycles of Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. *Cancers*, **2021**, 13,	6.6	1
94	The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. *Prostate*, **2021**, 81, 765-771	4.2	1
93	Contemporary patterns of presentation, diagnostics and management of upper tract urothelial cancer in 101 centres: the Clinical Research Office of the Endourological Society Global upper tract urothelial carcinoma registry. *Current Opinion in Urology*, **2021**, 31, 354-362	2.8	1
92	Health-related quality of life in bladder cancer patients: general and cancer-specific instruments. Part 1. *Current Opinion in Urology*, **2021**, 31, 297-303	2.8	1
91	Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomy. *International Journal of Clinical Oncology*, **2021**, 26, 1707-1713	4.2	1
90	Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 789.e9-789.e17	2.8	1
89	Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 785.e19-785.e27	2.8	1
88	The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia. *Advances in Anatomic Pathology*, **2021**, 28, 179-195	5.1	1

87	Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile: an updated systematic review and meta-analysis. *Minerva Urology and Nephrology*, **2021**,	2.3	1
86	Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. *European Urology*, **2016**, 70, 205-6	10.2	1
85	Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy. *Canadian Urological Association Journal*, **2020**, 14, E173-E179	1.2	1
84	Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. *World Journal of Urology*, **2019**, 37, 1631-1637	4	1
83	Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients. *World Journal of Urology*, **2020**, 38, 1525-1533	4	1
82	The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC). *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 423-432	2.8	1
81	Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management. *Current Opinion in Urology*, **2020**, 30, 457-466	2.8	1
80	Making a case "against" focal therapy for intermediate-risk prostate cancer. *World Journal of Urology*, **2021**, 39, 719-728	4	1
79	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. *BJU International*, **2021**, 127, 528-537	5.6	1
78	The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 369.e9-369.e17	2.8	1
77	Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review. *Arab Journal of Urology Arab Association of Urology*, **2020**, 19, 59-66	1.7	1
76	Functional Outcomes after Local Salvage Therapies for Radiation-Recurrent Prostate Cancer Patients: A Systematic Review. *Cancers*, **2021**, 13,	6.6	1
75	The effect of race on survival after local therapy in metastatic prostate cancer patients. *Canadian Urological Association Journal*, **2019**, 13, 175-181	1.2	1
74	Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis. *International Journal of Urology*, **2018**, 25, 929-936	2.3	1
73	The Consequences of Inadvertent Radical Nephrectomy in the Treatment of Upper Tract Urothelial Carcinoma. *Urology*, **2021**, 154, 127-135	1.6	1
72	Metastatic clear cell renal cell carcinoma: computed tomography texture analysis as predictive biomarkers of survival in patients treated with nivolumab. *International Journal of Clinical Oncology*, **2021**, 26, 2087-2093	4.2	1
71	Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 764-773	2.8	1
70	Alternating Cystoscopy with Bladder EpiCheck in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. *Bladder Cancer*, **2021**, 7, 307-315	1	1

69	Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries. *Clinical Genitourinary Cancer*, **2021**, 19, e255-e263	3.3	1
68	Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer. *Current Oncology*, **2021**, 28, 3692-3704	2.8	1
67	Survival after radical prostatectomy versus´radiation therapy in clinical node-positive prostate cancer.. *Prostate*, **2022**,	4.2	1
66	Lower urinary tract symptoms are associated with clinically relevant depression, anxiety, and stress symptoms.. *Aging Male*, **2022**, 25, 62-66	2.1	1
65	Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.. *European Urology Open Science*, **2022**, 39, 14-21	0.9	1
64	Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer.. *Journal of Cellular and Molecular Medicine*, **2021**,	5.6	1
63	Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis.. *Journal of Robotic Surgery*, **2021**, 1	2.9	1
62	Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review.. *Translational Cancer Research*, **2022**, 11, 908-917	0.3	1
61	Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity.. *International Urology and Nephrology*, **2022**, 1	2.3	1
60	How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?. *European Urology Oncology*, **2021**, 4, 663-669	6.7	0
59	Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth© Letter to the Editor´re: Malte Rieken, Shahrokh F. Shariat, Luis A. Kluth, et al. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.05.038. *European Urology*, **2015**, 68, e104-5	10.2	0
58	Prognostic models to help predict patient responses to intravesical immunotherapy. *Expert Review of Precision Medicine and Drug Development*, **2020**, 5, 243-251	1.6	0
57	Epidemiology and Sociocultural Differences for Bladder Cancer **2019**, 291-301		0
56	Neoadjuvant therapy in urothelial cancer. *Memo - Magazine of European Medical Oncology*, **2019**, 12, 329-333	0.3	0
55	Ischemic priapism in a 12-year old patient associated with coronavirus disease 2019 (COVID-19): a case report.. *Urology*, **2022**,	1.6	0
54	Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer.. *World Journal of Urology*, **2022**, 1	4	0
53	Association of statins use and mortality outcomes in prostate cancer patients who received androgen deprivation therapy: a systematic review and meta-analysis.. *Central European Journal of Urology*, **2021**, 74, 484-490	0.9	0
52	Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies.. *Molecular Cancer*, **2022**, 21, 7	42.1	0

51	Fighting the Œtobacco epidemicO A call to action to identify Targeted Intervention Points (TIPs) for better counseling patients with urothelial cancer. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 793-796	2.8	0
50	Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities. *Clinical Genitourinary Cancer*, **2020**, 18, e450-e456	3.3	0
49	Impact of Sex on Response to Neoadjuvant Chemotherapy in Patients with Upper-tract Urothelial Cancer. *European Urology Open Science*, **2020**, 19, 16-19	0.9	0
48	Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy. *World Journal of Urology*, **2021**, 39, 3771-3779	4	0
47	Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy. *Current Opinion in Urology*, **2021**, 31, 291-296	2.8	0
46	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. *International Journal of Clinical Oncology*, **2021**, 26, 1729-1735	4.2	0
45	Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response. *Current Oncology*, **2021**, 28, 2881-2892	2.8	0
44	Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. *Turkish Journal of Urology*, **2021**, 47, S33-S44	1.3	0
43	Radical Cystectomy vs. Multimodality Treatment in T2N0M0 Bladder Cancer: A Population-based, Age-matched Analysis. *Clinical Genitourinary Cancer*, **2021**, 19, e264-e271	3.3	0
42	Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. *Immunotherapy*, **2021**, 13, 917-929	3.8	0
41	The impact of sex and age on distribution of metastases in patients with renal cell carcinoma. *International Journal of Clinical Oncology*, **2021**, 26, 962-970	4.2	0
40	Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature. *Translational Andrology and Urology*, **2021**, 10, 4051-4061	2.3	0
39	Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration.. *World Journal of Urology*, **2022**, 1	4	0
38	Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables.. *Journal of Racial and Ethnic Health Disparities*, **2022**, 1	3.5	0
37	The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis.. *International Journal of Surgical Pathology*, **2022**, 10668969221095173	1.2	0
36	Feasibility and Optimal Time Point of [68Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery. *European Urology Open Science*, **2022**, 40, 117-124	0.9	0
35	Metastatic stage vs complications at radical nephrectomy with inferior vena cava thrombectomy. *Surgical Oncology*, **2022**, 101783	2.5	0
34	Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement. *European Urology*, **2017**, 72, 474-475	10.2	

33	Re: Adjuvant Chemotherapy vs Observation for Patients with Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. *European Urology*, **2017**, 72, 1025-1026	10.2
32	Chirurgische Therapie des Harnblasenkarzinoms. *InFo Hämatologie + Onkologie*, **2019**, 22, 12-17	0
31	Molecular markers for screening, detection and prognosis of bladder cancer **2015**, 62-88	
30	Robot-assisted partial nephrectomy: systematic review of functional results. *Current Opinion in Urology*, **2018**, 28, 123-131	2.8
29	Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. *European Urology*, **2018**, 74, 680-681	10.2
28	The Role of Urologist **2018**, 101-112	
27	Epidemiology and Sociocultural Differences for Bladder Cancer **2018**, 1-11	
26	Das fortgeschrittene Urothelkarzinom des oberen Harntrakts. *Uro-News*, **2019**, 23, 38-43	0
25	Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer. *European Urology*, **2017**, 72, 471-472	10.2
24	Reply to Pascal Mouracade© Letter to the Editor re: Thomas F. Chromecki, Eugene K. Cha, Harun Fajkovic, et al. The Impact of Tumor Multifocality on Outcomes in Patients Treated with Radical Nephroureterectomy. Eur Urol 2012;61;245□3. *European Urology*, **2012**, 62, e77-e78	10.2
23	Words of wisdom. Re: Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V. *European Urology*, **2009**, 56, 573-5	10.2
22	Prognostic Factors and Predictive Tools in Upper Tract Urothelial Carcinoma **2018**, 15-32	
21	Exploring the molecular basis of sexual dimorphism in bladder cancer. *Nature Reviews Urology*, **2020**, 17, 487-488	5.5
20	Reply by Authors. *Journal of Urology*, **2020**, 204, 302	2.5
19	Racial differences in the distribution of bladder cancer metastases: a population-based analysis. *Central European Journal of Urology*, **2020**, 73, 407-415	0.9
18	Prognostics Factors, Molecular Markers, and Predictive Tools in Upper Tract Urothelial Carcinoma **2015**, 91-117	
17	Risk stratification of high-grade Ta, CIS, and T1 urothelial carcinoma of the bladder18-25	
16	Contemporary concepts and controversies in the diagnosis and management of urothelial carcinoma. *Translational Andrology and Urology*, **2016**, 5, 633-635	2.3

15	Reply to Francesco Montorsi, Marco Bandini, and Andrea Necchi's Letter to the Editor re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. Eur Urol Focus 2020;6:1233-9. *European Urology Focus*, **2021**,	5.1
14	Benefit of Adjuvant Chemotherapy After Radical Cystectomy for Treatment of Urothelial Carcinoma of the Bladder in the Elderly: An International Multicenter Study. *Bladder Cancer*, **2021**, 7, 173-185	1
13	Single-lesion PSMA protein expression and response to Lu-177 PSMA therapy in patients with castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2021**, 39, 5065-5065	2.2
12	Das Harnblasenkarzinom der Frau. *Journal Fur Urologie Und Urogynakologie*, **2021**, 28, 29-33	0
11	Reply to Alba Fiorentino, Angelo Errico, and Marcello Scarcia's Letter to the Editor re: Marco Moschini, Emanuele Zaffuto, Pierre I. Karakiewicz, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol 2019;75:319-28. Radiation Therapy Versus	10.2
10	Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer. *European Urology*, **2020**, 77, 132-133	10.2
9	Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [Ga]Ga-PSMA ligand PET/CT(MRI). *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 439-447	6.2
8	Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. *European Urology*, **2021**, 79, 163-164	10.2
7	Organerhaltende Therapie beim Urothelkarzinom des oberen Harntraktes (UTUC). *Journal Fur Urologie Und Urogynakologie*, **2018**, 25, 72-77	0
6	Über Exzellenz und Reputation in Medizin und Urologie **2021**, 67-94	
5	Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant. *Prostate*, **2021**, 81, 1294-1302	4.2
4	Risk Stratification of Upper Tract Urothelial Carcinoma for Kidney-Sparing Surgery **2021**, 387-402	
3	Recent pharmacological approaches for the treatment of renal cell carcinoma.. *Expert Review of Clinical Pharmacology*, **2022**, 1-9	3.8
2	Randomized comparator-controlled study evaluating efficacy and safety of pembrolizumab plus Bacillus Calmette-Guérin (BCG) in patients with high-risk nonmuscle-invasive bladder cancer (HR NMIBC): KEYNOTE-676 cohort B.. *Journal of Clinical Oncology*, **2022**, 40, TPS597-TPS597	2.2
1	The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy. *European Urology Open Science*, **2022**, 41, 74-80	0.9